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ABSTRACT 
A hot - melt extruded composition having finely divided 
drug - containing particles dispersed within a polymeric and / 
or lipophyllic carrier matrix is provided . The carrier softens 
or melts during hot - melt extrusion but it does not dissolve 
the drug - containing particles during extrusion . As a result , a 
majority or at least 90 % wt . of the drug - containing particles 
in the extrudate are deaggregated during extrusion into 
essentially primary crystalline and / or amorphous particles . 
PEO is a suitable carrier material for drugs insoluble in the 
solid state in this carrier . Various functional excipients can 
be included in the carrier system to stabilize the particle size 
and physical state of the drug substance in either a crystal 
line and / or amorphous state . The carrier system is comprised 
of at least one thermal binder , and may also contain various 
functional excipients , such as : super - disintegrants , antioxi 
dants , surfactants , wetting agents , stabilizing agents , retar 
dants , or similar functional excipients . A hydrophilic poly 
mer , such as hydroxypropyl methylcellulose ( HPMC E15 ) , 
polyvinyl alcohol ( PVA ) , or poloxamer , and / or a surfactant , 
such as sodium lauryl sulfate ( SLS ) , can be included in the 
composition . A process for preparing the extrudate is con 
ducted at a temperature approximating or above the soften 
ing or melting temperature of the matrix and below the point 
of solubilization of drug - containing particles in the carrier 
system , and below the recrystallization point in the case of 
amorphous fine drug particles . 
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STABILIZED HME COMPOSITION WITH hot - melt extrusion techniques . Rosenberg and Breitenbach 
SMALL DRUG PARTICLES have produced solid solutions by melt extruding the active 
substance in a nonionic form together with a salt and a 
This application is a divisional of U . S . application Ser . polymer , such as polyvinylpyrrolidone ( PVP ) , vinylpyrroli 
No . 11 / 718 , 620 , filed Nov . 19 , 2007 , now U . S . Pat . No . 5 dinone / vinylacetate ( PVPVA ) copolymer , or a hydroxyalky 
9 , 504 , 658 , which is a national phase application under 35 lcellulose ( 12 ) . Six et al . , Brewster et al . , Baert et al . , and 
U . S . C . $ 371 of International Application No . PCT / US2005 / Verreck et al . have produced solid dispersions of itracon 
040535 , filed Nov . 9 , 2005 , which claims priority to U . S . azole with improved dissolution rates by hot - melt extrusion 
provisional application No . 60 / 681 , 279 , filed May 16 , 2005 , with various polymeric carriers including hydroxypropylm 
and U . S . provisional application No . 60 / 626 , 400 , filed Nov . 10 ethylcellulose , Eudragit E100 , PVPVA , and a combination 
9 , 2005 . The entire text of each of the above referenced of Eudragit E100 and PVPVA ( 13 - 19 ) . Rambaldi et al . 
disclosures is specifically incorporated herein by reference . produced solid dispersions of itraconazole by hot - melt 
extrusion with hydroxypropyl - beta - cyclodextrin and 
FIELD OF THE INVENTION hydroxypropylmethylcellulose for the improvement of 
15 aqueous solubility ( 20 ) . Verreck et al . produced solid dis 
The present invention concerns a hot - melt extruded phar - persions of a water - insoluble microsomal triglyceride trans 
maceutical composition comprising a therapeutic compound fer protein inhibitor with improved bioavailability by hot 
dispersed as fine particles in a stabilizing and non - solubi - melt extrusion ( 21 ) . Hulsmann et al . produced solid 
lizing carrier system and a method of preparation thereof . dispersions of the poorly water soluble drug 17 B - estradiol 
The invention also concerns a process of preparing a hot - 20 with increased dissolution rate by hot melt extrusion with 
melt extruded pharmaceutical composition wherein small polymeric carriers such as polyethylene glycol , PVP , and 
amorphous or crystalline particles of a therapeutic com - PVPVA along with various non - polymeric additives ( 22 ) . 
pound are dispersed as individual particles during hot - melt Forster et al . produced amorphous glass solutions with the 
extrusion and after storage for extended periods of time . The poorly water soluble drugs indomethacin , lacidipine , nife 
hot - melt extruded composition provides stable release prop - 25 dipine , and tolbutamide in PVP and PVPVA demonstrating 
erties of the therapeutic compound over an extended period improved dissolution compared with the crystalline forms 
of storage . ( 23 ) . In this article , it is also seen that after storage of the 
extrudates at 25° C . and 75 % relative humidity only com 
BACKGROUND OF THE INVENTION positions containing indomethacin and polymer in a one to 
30 one ratio remained completely amorphous . Formulations of 
Many researchers have utilized hot - melt extrusion tech - the remaining drugs and formulations with increased indo 
niques to produce pharmaceutical preparations in various methacin concentration showed recrystallization on storage . 
forms . Zhang and McGinity utilized hot - melt extrusion to This recrystallization was shown to significantly decrease 
produce sustained release matrix tablets with PEO and the dissolution rate of the active . It should also be noted that 
polyvinyl acetate , and more generally non - film preparations 35 stability studies were not performed at elevated temperatures 
with polyethylene oxide ( PEO ) ( 1 - 3 ) . Kothrade et al . dem - in this study . It would be expected that elevated temperatures 
onstrated a method of producing solid dosage forms of would increase the occurrence and extent of recrystalliza 
active ingredients in a vinyllactam co - polymeric binder by tion . 
hot - melt extrusion ( 4 ) . Aitken - Nichol et al . used hot - melt The previous reference reveals the inherent instability of 
extrusion methods to produce acrylic polymer films con - 40 amorphous dispersions produced by hot - melt extrusion tech 
taining the active lidocaine HC1 ( 5 ) . Grabowski et al . niques . Although many articles demonstrate the production 
produced solid pharmaceutical preparations of actives in of amorphous solid dispersions and the resulting improve 
low - substituted hydroxypropyl cellulose using hot - melt m ent of drug dissolution rate , very few discuss the stability 
extrusion techniques ( 6 ) . Repka and McGinity used hot - melt of such preparations on storage . From the work of Foster et 
extrusion processes to produce bioadhesive films for topical 45 al . and an understanding of the thermodynamics of amor 
and mucosal adhesion applications for controlled drug deliv - phous systems , it can be concluded that recrystallization of 
ery to various mucosal sites ( 7 , 8 ) . Robinson et al . produced amorphous solid dispersion formulations on storage is a 
effervescent granules with controlled rate of effervescence common problem . The amorphous state is thermodynami 
using hot melt extrusion techniques ( 3 ) . Breitenbach and cally metastable , and therefore it is expected that amorphous 
Zettler produced solid spherical materials containing bio - 50 compounds will assume a stable crystalline conformation 
logically active substances via hot - melt extrusion ( 9 ) . De with time , as well as in response to perturbations such as 
Brabander et al . demonstrated sustained release mini - matri - elevations in temperature and exposure to moisture . In an 
ces by utilizing hot - melt extrusion techniques ( 10 , 11 ) . extruded formulation , amorphous drug particles will 
Pharmaceutical formulations comprised of active com - agglomerate and crystallize with increasing storage time , 
pounds finely and homogenously dispersed in one or more 55 elevated temperature , or exposure to moisture , essentially 
polymeric carriers have been described as solid dispersions , precipitating out of the carrier . This progression towards 
glass solutions , molecular dispersions , and solid solutions . phase separation during storage results in a time dependant 
The term solid dispersion has been used as a general term to dissolution profile . A change in dissolution rate with time 
describe pharmaceutical preparations in which the active precludes the successful commercialization of a pharmaceu 
compound is dispersed in an inert excipient carrier in a size 60 tical product . 
range from course to fine . Glass solution , molecular disper - The article by Foster et al . also demonstrates the limita 
sion , and solid solution refer specifically to preparations in tion of drug loading in amorphous solid dispersions by 
which amorphous forms of a crystalline active compound hot - melt extrusion . It is seen in this article that recrystalli 
are formed in - situ and dispersed within the polymer matrix zation of indomethacin on storage is induced when the 
during the hot - melt extrusion process . 65 concentration of indomethacin is increased from 1 : 1 to 4 : 1 
Many researchers have produced such preparations with drug to polymer ratio . Six et al . demonstrated immiscibility 
various active compounds and polymeric carriers using of itraconazole and Eudragit E100 when extruded at 140° C . 
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and phase separation on processing at concentrations greater Freezing techniques for producing micro or nano - sized 
than 13 % and 20 % ( w / w ) when extruded at 168° C . and 180° drug particles are listed below along with their respective 
C . , respectively ( 14 - 16 ) . Six et al . also demonstrated a single illustrating references : a ) spray freezing into liquid ( SFL ) — 
phase system of itraconazole and PVPVA at drug concen - ( 34 ) WO02060411 USPTO App . # 2003054042 and 
trations up to 80 % ( w / w ) , however only a slight improve - 5 2003024424 ; and b ) ultra rapid freezing ( URF ) ( 35 ) . 
ment of the dissolution rate was achieved ( 16 ) . Kearney et It should be noted that fine drug particles produced by 
al . showed phase separation of an anti - inflammatory drug , solution - based phase separation or rapid freezing techniques 
CI - 987 , in PVP at drug concentrations greater than 19 % are often amorphous in nature . Theses amorphous particles 
( w / w ) for solid dispersions prepared by solvent evaporation can be stabilized by complexation or coating during the 
methods ( 24 ) . Verreck et al . demonstrated an amorphous 10 production process with one or more excipient carriers 
dispersion of itraconazole in HPMC at a concentration of having high melting points or glass transition temperatures . 
40 % drug , with improved dissolution rate and chemical and Stabilized amorphous fine drug particles can be formulated 
physical stability for up to 6 months at various temperature into the present preparation in the same manner as crystal 
and humidity conditions ( 17 ) . In a follow up article , Six et line fine drug particles . The high shear of the hot - melt 
al . showed phase separation of itraconazole from identical 15 extrusion process will effectively deaggregate and disperse 
HPMC carrier systems at a concentration of 60 % drug ( 13 ) . the amorphous drug particles ( likely to be aggregated before 
The difficulty of producing stable single phase amorphous extrusion due to high surface energy as stated in the next 
dispersions of high drug loading can be seen from references paragraph ) into the stabilizing and non - solubilizing carrier 
such as those given above . The appearance of a second phase thereby separating the aggregated particles into primary 
of the active compound on processing or on storage would 20 particles that are stabilized against aggregation and agglom 
result in a time dependent biphasic dissolution profile , and eration on processing and storage by the carrier system . The 
would therefore not be considered an acceptable pharma - excipient system with which the amorphous drug particles 
ceutical preparation . are complexed or coated will prevent recrystallization dur 
Although there have been many reports of successful ing hot - melt extrusion and storage of the amorphous drug 
production of solid dispersions by hot - melt extrusion that 25 containing particle domains that are dispersed in the stabi 
show improved dissolution rates of poorly water soluble lizing and non - solubilizing carrier matrix . The benefit of this 
drugs , the absence of numerous marketed products based on form of an amorphous dispersion compared to a traditional 
this technology is evidence that stability problems remain a amorphous dispersion is that the formation of fine amor 
major obstacle for successful commercialization of such a phous drug particles is not dependent on the solubility of the 
pharmaceutical preparation . 30 drug in the carrier system , since the amorphous drug par 
There are several methods well known in the pharmaceu - ticles are not formed in situ by the solubilization of the 
tical literature for producing fine drug particles in the micro c rystalline drug particles by the carrier system . 
or nanometer size range . These methods can be divided into It has been reported that fine drug particles produced by 
three primary categories : ( 1 ) mechanical micronization ( 2 ) processes such as those listed above exhibit high surface 
solution based phase separation and ( 3 ) rapid freezing 35 energy resulting in strong cohesive forces between particles . 
techniques . Zimon showed that powders of fine particles are likely to 
Mechanical micronization is most commonly done by aggregate because the force of detachment is dependent on 
milling techniques that can produce particles in the range of particle mass which is small in the case of fine particles ( 36 ) . 
1 to 20 microns . The most common processes utilized for The forces of cohesion between individual fine particles are 
this type of mechanical particle size reduction are ball and 40 therefore greater than the forces of detachment , and thus 
jet milling . Milling drug particles by these processes can particle aggregates form . French et al . demonstrated that the 
reduce primary drug particles to micron - sized particles forces of cohesion between particles increase with decreas 
however high surface energy results in aggregation of pri - ing particle size ( 37 ) . Therefore , the extent of aggregation is 
mary particles which to an extent negates the milling pro - increased as particle size is reduced . 
cess . Nykamp et al . and Carstensen et al . demonstrated a 45 Aggregation of fine particles results in an increase in the 
melt grinding and jet milling technique to produce drug apparent particle size , consequently , particle size reduction 
loaded microparticles of polylactic acid or polylactic - co - is somewhat negated . In order to achieve the full benefit of 
glycolic acid with mean particle size in the range of four to particle size reduction , i . e . accelerated dissolution rate , 
six microns ( 25 , 26 ) . aggregates must be reduced to individual particles when 
There are many solution based phase separation processes 50 dosed . Lui and Stewart demonstrated a reduction in disso 
documented in the pharmaceutical literature for producing lution rate of benzodiazepines with an increasing extent of 
micro and nano - sized drug particles . Some of the more particle aggregation ( 38 ) . 
commonly known processes are spray drying , emulsifica - Particle agglomeration with storage also causes an 
tion / evaporation , emulsification / solvent extraction , and increase in apparent particle size , and a corresponding 
complex coacervation . Some of the lesser - known processes 55 decrease in dissolution rate . Ticehurst et al . demonstrated 
are , for the sake of brevity , listed below along with their agglomeration of micronized revatropate hydrobromide 
respective illustrating references : a ) gas antisolvent precipi - when stored at greater than 25 % relative humidity ( 39 ) . 
tation ( GAS ) — ( 27 ) and WO9003782 EP0437451 Therefore , in the production of an ideal solid dosage form 
EP0437451 DK59091 ; b ) precipitation with a compressed containing fine drug particles , aggregates would be sepa 
antisolvent ( PCA ) ( 28 ) and U . S . Pat . No . 5 , 874 , 029 ; c ) 60 rated and stabilized as individual particles by a carrier 
aerosol solvent extraction system ( ASES ) - ( 29 ) ; d ) evapo - system during processing . The carrier system would also 
rative precipitation into aqueous solution ( EPAS ) – ( 30 ) US function to impede particle aggregation and agglomeration 
patent application 20040067251 ; e ) supercritical antisolvent on storage at ambient and accelerated temperature and 
( SAS ) - ( 31 ) ; f ) solution - enhanced dispersion by supercriti - humidity conditions . 
cal fluids ( SEDS ) - ( 32 ) ; g ) rapid expansion from supercriti - 65 There have been few published reports of the successful 
cal to aqueous solutions ( RESAS ) - ( 33 ) ; and h ) anti - solvent incorporation of fine drug particles into a traditional dosage 
precipitation . forms . Hu et al . developed an immediate release tablet of 
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Danazol micronized powder by the SFL process , however product is a solid dispersion of fine particles stabilized by the 
only 5 . 3 % drug loading was reported ( 40 ) . Authors have also carrier system , wherein the composition maintains primary 
reported on the oral delivery of fine drug particles in the particle integrity on storage . 
form of a stabilized liquid suspension ( 41 , 42 ) . There are two One aspect of the invention provides a hot - melt extruded 
important limitations of delivering fine drug particle formu - 5 pharmaceutical composition comprising an effective amount 
lations in a liquid suspension , namely the instability of the of a therapeutic compound dispersed as fine particles in a 
preparation and the commercial limitation of shipping sus - stabilizing and non - solubilizing carrier system . The fine 
pensions . Liquid suspensions are known to be unstable on drug - containing particles are dispersed within the carrier 
storage due to agglomeration , and sedimentation , as well as system via hot - melt extrusion as discrete particles in a size 
caking of suspended particles . Commercially it is not ideal range of less than one hundred microns , less than twenty 
to formulate a pharmaceutical preparation as a suspension microns , or less than five microns . A substantial majority , 
due to the cost of shipping the excess weight of the liquid e . g . at least 75 % wt . , of the particles are not agglomerated 
vehicle , as compared to a solid dosage form . or aggregated by the hot - melt extrusion process used to 
Prior art examples such as those given above demonstrate 15 prepare the composition . In other words , at least 75 % wt . of 
the ongoing need for the advantageous properties of the the particles are present in unagglomerated form . 
present invention for the delivery of drug from a hot - melt Another aspect of the invention provides a method of 
extruded composition comprising fine drug particles . preparing a hot - melt extruded pharmaceutical composition 
comprising fine drug - containing particles dispersed in a 
SUMMARY OF THE INVENTION 20 stabilizing and non - solubilizing thermally processable car 
rier , the method comprising the steps of : 
The present invention seeks to overcome some or all of providing a charge of fine drug - containing particles of a 
the disadvantages inherent in the above - mentioned compo - therapeutic compound ; 
sitions and methods . The present invention allows for high providing a charge of stabilizing and non - solubilizing hot 
drug loading of fine drug particles in a stable and easily 25 melt extrudable carrier ; and 
portable solid dosage form . In addition , the preparation can mixing and hot - melting extruding the charges to form the 
be formulated to provide a variety of drug release profiles to hot - melt extruded pharmaceutical composition ; wherein a 
most sites of administration . substantial majority of the fine drug particles are not 
The present invention relates to pharmaceutical formula agglomerated or aggregated as a result of the step of 
tions comprised of active compounds finely and homog - 30 hot - melt extruding . 
enously dispersed in one or more polymeric carriers that are The invention also provides a pharmaceutical solid dos 
produced by hot - melt extrusion techniques . Such prepara age form having a stabilized release profile , the dosage form 
tions have been described as solid dispersions , glass solu comprising a hot - melt extruded pharmaceutical composition 
tions , molecular dispersions , and solid solutions . comprising fine drug particles of a therapeutic compound 35 dispersed in a stabilizing and non - solubilizing carrier . The composition herein may be formulated to avoid the » In some embodiments , the stabilizing and non - solubiliz problem of phase separation with increasing concentration ing carrier is hot - melt extrudable meaning it can be hot by incorporating into the carrier system crystalline fine drug melt - extruded with no significant thermal degradation . The particles or stabilized amorphous fine drug particles pro stabilizing and non - solubilizing carrier can also be thermally 
duced prior to extrusion . Additionally , by dispersing crys - 40 processable , meaning it softens and melts at the processing 
talline or stabilized , preformed amorphous fine drug par temperature with no significant thermal degradation . In 
ticles into the non - solubilizing , stabilizing carrier system via some embodiments , a major portion of the stabilizing and 
the high shear extrusion process , problems of recrystalliza non - solubilizing carrier is selected from the group consisting 
tion of amorphous domains , as well as particle aggregation of polyethylene oxide ; polypropylene oxide ; polyvinylpyr 
and agglomeration are overcome . 45 rolidone ; polyvinylpyrrolidone - co - vinylacetate ; acrylate 
The present invention addresses the problem of physical and methacrylate copolymers ; polyethylene ; polycaprolac 
instability of traditional solid dispersions and the resulting tone ; polyethylene - co - polypropylene ; alkylcelluloses such 
time - dependent drug release profile by dispersing , via hot - as methylcellulose ; hydroxyalkylcelluloses such as 
melt extrusion , fine drug particles in a thermodynamically hydroxymethylcellulose , hydroxy ethylcellulose , hydroxy 
stable crystalline state , or in a stabilized amorphous state 50 propylcellulose , and hydroxybutylcellulose ; hydroxyalkyl 
into a polymeric carrier which will act to separate and isolate alkylcelluloses such as hydroxyethyl methylcellulose and 
individual drug particles , thus preventing aggregation and hydroxypropyl methylcellulose ; starches , pectins ; polysac 
agglomeration during processing and on storage . The carrier charides such as tragacanth , gum arabic , guar gum , sucrose 
is formulated such that it will not substantially compromise stearate , Xanthan gum , lipids , waxes , mono , di , and tri 
the integrity of the individual drug particles during extru - 55 glycerides , cetyl alcohol , steryl alcohol . parafilm waxes and 
sion , such as by dissolving all or a significant part of the drug the like , hydrogenated vegetable and castor oil , glycerol 
particles . monostearte , polyolefins including xylitol , mannitol , and 
This invention also relates to the field of fine particle Sorbitol , alpha hydroxyl acids including citric and tartaric 
technology in that fine particles produced from any fine acid edipic acid meleaic acid malic acid , citric acid , enteric 
particle production technology can be incorporated into the 60 polymers such as CAP , HPMC AS , shellac , and a combi 
claimed pharmaceutical preparation . nation thereof . The stabilizing and non - solubilizing carrier 
The present invention can be formulated to achieve an can further comprise surfactant carbohydrate , a high HLB 
advantageous dosage form comprising fine drug particles . surfactant , a low HLB surfactant , tablet excipient , filler , 
Processing powders of fine drug particles with a stabilizing binder , disintegrant , super disintegrant , protein , peptide , 
and non - solubilizing carrier system by hot - melt extrusion 65 enzyme , hormone , protein or a combination thereof . In some 
one or more times reduces particle aggregation and stabi - embodiments , the stabilizing and non - solubilizing carrier is 
lizes them as individual fine drug particles . The resulting selected from the group consisting of fixed oil , nonpolar 
US 9 , 730 , 894 B2 
vehicle , and water miscible ingredients including alcohols Example 9 and Example 10 before and after storage at 
and glycols such as the PEGs ( poly ( ethylene glycol ) ) and conditions of 40° C . and 75 % relative humidity in aluminum 
PG ( propylene glycol ) . induction sealed high density polyethylene bottles for a 
When provided as a pharmaceutical composition , the period of two weeks . 
pharmaceutical composition ( or dosage form ) can provide 5 FIG . 14 depicts DSC thermograms obtained according to 
an immediate or rapid release of therapeutic compound after Example 3 for samples prepared according to Example 13 , 
exposure to an environment of use . Alternatively or addi samples prepared according to Example 14 , a physical 
tionally , the pharmaceutical composition ( or dosage form ) mixture of crystalline CBM with the excipient components 
can be adapted to provide an extended release of therapeutic of examples 13 and 14 , and PVP K25 . 
compound after exposure to an environment of use . Like - 10 FIG . 15 depicts X - ray diffraction patterns obtained 
wise , the pharmaceutical composition ( or dosage form ) can according to Example 11 for poloxamer 407 : PEO ( 7 : 3 ) 
be adapted to provide a delayed release of therapeutic placebo extrudate , a physical mixture of crystalline CBM 
compound after exposure to an environment of use . with the excipient components of Examples 13 and 14 , 
A dosage form containing the pharmaceutical composi - samples produced according to Example 14 , samples pro 
tion can be selected from the group consisting of bead , 15 duced according to Example 13 , and bulk CBM . 
tablet , pill , granulate , powder , capsule , tube , strand , cylin - FIG . 16 depicts comparative dissolution profiles obtained 
der , or film and can be further processed into a powder , according to Example 12 for samples made according to 
pellets , or powder coatings for application on various sub - Example 13 and Example 14 . 
strates . FIG . 17 depicts comparative dissolution profiles for 
The pharmaceutical dosage form can be formulated , for 20 samples made according to Example 13 and Example 14 in 
example , for transdermal , transmucosal , rectal , pulmonary , which the amount of CBM added to each dissolution vessel 
nasal , vaginal , ocular , or otic drug delivery , or as an implant - ( 200 mg /900 ml ) was several times greater than the equi 
able drug delivery device . librium saturation solubility . 
FIG . 18 depicts comparative dissolution profiles for 
BRIEF DESCRIPTION OF THE FIGURES 25 samples made according to Example 13 and samples made 
according to Example 14 before and after storage according 
The following figures form part of the present description to Example 4 at conditions of 40° C . and 75 % relative 
and describe exemplary embodiments of the claimed inven humidity in aluminum induction sealed high density poly 
tion . The skilled artisan will , in light of these figures and the ethylene bottles for a period of two weeks . 
description herein , be able to practice the invention without 30 FIG . 19 depicts DSC thermograms obtained according to 
undue experimentation . Example 3 for samples produced according to Example 15 , 
FIGS . 1a and b depict cross - sectional front elevation of an HPMC E3 , samples produced according to Example 16 , a 
exemplary embodiment of a hot - melt extruded composition physical mixture of crystalline KCZ with the excipient 
according the invention . components of Examples 15 and 16 , and bulk ketoconazole . 
FIGS . 2a - 2c , 3a - 3c , 4a - 4c , 5a - 5c and 6a - 6c depict elec - 35 FIG . 20a - 20b depict SEM images obtained according to 
tron micrographs of control and exemplary sample formu Example 2 for samples prepared according to Example 17 
lations prepared as described herein . ( FIG . 20a ) and Example 18 ( FIG . 206 ) . The circles in FIG . 
FIGS . 2d , 3d , 4d , 5d , and 6d depict DSC thermograms for 20b highlight some of the more apparent fine crystals of 
control and exemplary sample formulations prepared as Danazol that are dispersed in the polymeric carrier matrix . 
described herein . 
FIGS . 7 - 8 depict comparative drug release profiles for DETAILED DESCRIPTION OF THE 
compositions of the invention before and after storage and INVENTION 
drug release profiles for a composition not made according 
to the invention . The drug - containing particles do not undergo substantial 
FIG . 9 depicts DSC thermograms obtained according to 45 aggregation or agglomeration during hot - melt extrusion 
Example 3 of PVP - stabilized amorphous ITZ particles ( Ex - and / or can be deaggregated to essentially primary particles 
ample 9 ) , extrudates containing PVP - stabilized amorphous during hot - melt extrusion due to the intense mixing and 
ITZ ( Example 10 ) , a physical mixture of crystalline ITZ agitation that occurs during the process . In some cases , the 
with the excipient components of Examples 9 and 10 , PVP extrudate may need to be processed more than one time 
K25 , and bulk crystalline ITZ . 50 through the extruder in order to provide the desired degree 
FIG . 10 depicts X - ray diffraction patterns obtained of deaggregation . As used herein , the term “ deaggregate ” , as 
according to Example 11 for poloxamer 407 : PEO ( 7 : 3 ) used in reference to the drug - containing particles , means to 
placebo extrudate , a physical mixture of crystalline ITZ with reduce a loosely bound agglomerate to essentially its pri 
the excipient components of examples 9 and 10 , extrudates mary constituent particles . As used herein , the term “ to 
containing PVP - stabilized amorphous ITZ ( Example 10 ) , 55 agglomerate ” or “ agglomeration ” , as used in reference to the 
bulk ITZ , and PVP - stabilized amorphous ITZ ( Example 9 ) . drug - containing particles means individual particles form a 
FIGS . 11a - 11d depict SEM ( scanning electron micros - larger particle . 
copy ) images obtained according to Example 2 for samples The fine drug - containing particles may be produced by 
prepared according to Example 9 ( FIG . 11a ) , a Poloxamer : one of many processes well known in the pharmaceutical 
PEO ( 7 : 3 ) placebo extrudate ( FIG . 11b ) , and samples pre - 60 literature . Such processes include mechanical milling by ball 
pared according Example 10 ( FIGS . 110 and 11d ) . mill , jet mill , or other similar grinding process ; solution 
FIG . 12 depicts comparative dissolution test ( drug based phase separation techniques such as spray drying , 
release ) profiles obtained according to Example 12 for emulsification / evaporation , emulsification / solvent extrac 
samples made according to Example 10 , samples made tion , complex coacervation , anti - solvent precipitation , gas 
according to Example 9 , and bulk ITZ . 65 antisolvent precipitation ( GAS ) , precipitation with a com 
FIG . 13 depicts comparative dissolution profiles obtained pressed antisolvent ( PCA ) , aerosol solvent extraction system 
according to Example 4 for samples made according to ( ASES ) , evaporative precipitation into aqueous solution 
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( EPAS ) , supercritical antisolvent ( SAS ) , solution - enhanced dispersed as primary particles into a non - solubilizing , sta 
dispersion by supercritical fluids ( SEDS ) , rapid expansion bilizing carrier system owing to the high shear of the 
from supercritical to aqueous solutions ( RESAS ) , pressure hot - melt extrusion process . 
induced phase separation ( PIPS ) ; or freezing techniques The nature of the carrier is such that the fine drug particles 
such as spray freezing into liquid ( SFL ) and ultra rapid 5 are not solubilized to a substantial degree in it during 
freezing ( URF ) . Detailed descriptions of these methods are extrusion , i . e . the drug particles are practically insoluble in 
included in references cited herein , the entire disclosures of the carrier system at the extrusion temperature . The carrier 
which are hereby incorporated by reference . also acts to stabilize the fine drug - containing particles such 
Examples 6 and 7 below provide exemplary detailed that particle aggregation or agglomeration does not occur , or 
procedures for the preparation of fine drug - containing par - only an insignificant amount , i . e . , about 5 % by number or 
ticles by SFL and EPAS , respectively . less of the drug - containing particles , of aggregation or 
The drug - containing particles can comprise one or more agglomeration does not occur , on processing , or upon stor 
drugs alone or a mixture of drug and one or more other age at various temperature and relative humidity conditions . 
adjunct stabilizers , such as sorbitan esters , polyoxyethylene Therefore , 5 % by number or less of the drug - containing 
sorbitan fatty acid esters , polyoxyethylene alkyl ethers , particles are present in the composition in agglomerated 
poloxamers ( polyethylene - polypropylene glycol block form . 
copolymers ) , sucrose esters , sodium lauryl sulfate , oleic As used herein , the term “ stabilizing and non - solubilizing 
acid , lauric acid , vitamin E TPGS , polyoxyethylated glyco - carrier ” refers to a material , or combination of materials , that 
lysed glycerides , dipalmitoyl phosphadityl choline , glycolic 20 is used as the matrix in which the drug - containing particles 
acid and salts , deoxycholic acid and salts , sodium fusidate , are dispersed during hot - melt extrusion . A stabilizing and 
cyclodextrins , polyethylene glycols , polyglycolyzed glycer - non - solubilizing carrier does not solubilize , or solubilizes an 
ides , polyvinyl alcohols , polyacrylates , polymethacrylates , insubstantial amount , e . g . about 10 % wt . or less , of the 
polyvinylpyrrolidones , phosphatidyl choline and deriva - drug - containing particles charged into the hot - melt extru 
tives , and cellulose derivatives . Excipients such as these can 25 sion apparatus . In addition , a stabilizing and non - solubiliz 
be used as adjunct stabilizers to complex or coat fine ing carrier stabilizes the average particle size of the fine drug 
particles in - situ for particle stabilization and / or improved particles by preventing or minimizing agglomeration and 
wetting . crystal growth on processing and storage . 
If materials other than drug are present in the drug The stabilizing and non - solubilizing carrier must be pro 
containing particles , such materials can be present up to an 30 cessable by hot - melt extrusion , meaning that the carrier 
amount of about or less than 90 % wt . , about or less than 50 % must be able to melt and / or soften sufficiently to permit 
wt . , or about or less than 10 % wt . of the weight of drug processing by hot - melt extrusion without substantial degra dation of the carrier or the drug - containing particles . As containing particles present . such , the stabilizing and non - solubilizing carrier can include The drug present in the drug - containing particles can be icles can be 35 a thermal binder , a pressure softenable binder , or a combi crystalline or amorphous in form or a combination thereof . nation thereof . 
The form of the drug in the drug - containing particle does not Exemplary thermal binders include : polyethylene oxide : 
change substantially during hot - melt extrusion . This means polypropylene oxide ; polyvinylpyrrolidone ; polyvinylpyr 
that the extent of crystallinity or amorphousness of the rolidone - co - vinylacetate : acrylate and methacrylate copoly 
drug - containing particles remains substantially the same 40 mers ; polyethylene ; polycaprolactone ; polyethylene - co 
after processing as it was before processing . Specifically , polypropylene ; alkylcelluloses such as methylcellulose ; 
less than about 5 % by weight of a crystalline charge of hydroxyalkylcelluloses such as hydroxymethylcellulose , 
drug - containing particles is made amorphous , and con - hydroxyethylcellulose , hydroxypropylcellulose , and 
versely less than about 5 % by weight of an amorphous hydroxybutylcellulose ; hydroxyalkyl alkylcelluloses such as 
charge of drug - containing particles is made crystalline by 45 hydroxyethyl methylcellulose and hydroxypropyl methyl 
hot - melt extrusion when such process is conducted as cellulose ; starches , pectins ; polysaccharides such as traga 
described herein . canth , gum arabic , guar gum , and xanthan gum . One 
The drug - containing particles typically have a mean par embodiment of the binder is poly ( ethylene oxide ) ( PEO ) , 
ticle diameter ( based on the volume size distribution when which can be purchased commercially from companies such 
approximated to a sphere ) of about 100 microns or less , 50 as the Dow Chemical Company , which markets PEO under 
about 50 microns or less , about 10 microns or less , or about the POLY OXTM trademark exemplary grades of which can 
1 micron or less . In some embodiments , the fine drug - include WSR N80 having an average molecular weight of 
containing particles will be stabilized in the nanometer range about 200 , 000 ; 1 , 000 , 000 ; and 2 , 000 , 000 . 
according to their method of preparation . Fine drug - con - Suitable grades of PEO can also be characterized by 
taining particles produced by mechanical means typically 55 viscosity of solutions containing fixed concentrations of 
range in size from 20 to 1 microns . Particles produced by PEO , such as for example : 
solution - based phase separation or rapid freezing techniques 
typically have mean particle diameters ranging from 10 
micrometers to 50 nanometers . Viscosity Range 
According to some embodiments of the invention , greater 60 POLYOX Aqueous Solution Water - Soluble Resin NF at 25° C . , mPa ' s than 75 % of the drug - containing particles have an average 
diameter of less than about 20 microns , 5 microns , or 1 POLYOX Water - Soluble Resin NF WSR N - 10 30 - 50 
micron depending on the method of preparation of the ( 5 % solution ) 
particles . POLYOX Water - Soluble Resin NF WSR N - 80 55 - 90 
( 5 % solution ) The loading of fine drug - containing particles in the hot - 65 POLYOX Water - Soluble Resin NF WSR N - 750 600 - 1 , 200 
melt extruded preparation may be up to concentrations of ( 5 % solution ) 
80 % . The particles are deaggregated and homogenously 
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- continued hydroxymethyl cellulose , carboxypolymethylene , polyeth ylene glycol , alginic acid , gelatin , polyvinyl alcohol , poly 
Viscosity Range vinylpyrrolidones , polyacrylamides , polymethacrylamides , 
POLYOX Aqueous Solution polyphosphazines , polyoxazolidines , poly ( hydroxyalkylcar 
Water - Soluble Resin NF at 25° C . , mPa ' s 5 boxylic acids ) , carrageenate alginates , carbomer , ammo 
POLYOX Water - Soluble Resin NF WSR - 205 4 , 500 - 8 , 800 nium alginate , sodium alginate , or mixtures thereof . 
( 5 % solution ) As used herein , the term “ antioxidant ” is intended to mean 
POLYOX Water - Soluble Resin NF WSR - 1105 8 , 800 - 17 , 600 an agent that inhibits oxidation and thus is used to prevent 
( 5 % solution ) 
POLYOX Water - Soluble Resin NF WSR N - 12K 400 - 800 the deterioration of preparations by oxidation due to the 
( 2 % solution ) 10 presence of oxygen free radicals or free metals in the 
POLYOX Water - Soluble Resin NF WSR N - 60K 2 , 000 - 4 , 000 composition . Such compounds include , by way of example 
( 2 % solution ) and without limitation , ascorbic acid , ascorbyl palmitate , POLYOX Water - Soluble Resin NF WSR - 301 1 , 650 - 5 , 500 butylated hydroxyanisole , butylated hydroxytoluene , hypo ( 1 % solution ) 
POLYOX Water - Soluble Resin NF WSR 5 , 500 - 7 , 500 phosphorous acid , monothioglycerol , sodium ascorbate , 
Coagulant ( 1 % solution ) sodium formaldehyde sulfoxylate and sodium metabisulfite 
POLYOX Water - Soluble Resin NF WSR - 303 7 , 500 - 10 , 000 and others known to those of ordinary skill in the art . Other ( 1 % solution ) suitable antioxidants include , for example , vitamin C , BHT , 
BHA , sodium bisulfite , vitamin E and its derivatives , propyl 
Suitable thermal binders that may or may not require a gallate or a sulfite derivative . 
plasticizer include , for example , EUDRAGITTM RS PO , 20 As used herein , the term " disintegrant ” is intended to 
EUDRAGITTM S100 , Kollidon SR ( poly ( vinyl acetate ) - co mean a compound used in solid dosage forms to promote the 
poly ( vinylpyrrolidone ) copolymer ) , ETHOCELTM ( ethylcel - disruption of a solid mass ( layer ) into smaller particles that 
lulose ) , HPC ( hydroxypropylcellulose ) , cellulose acetate are more readily dispersed or dissolved . Exemplary disin 
butyrate , poly ( vinylpyrrolidone ) ( PVP ) , poly ( ethylene gly tegrants include , by way of example and without limitation , 
col ) ( PEG ) , poly ( ethylene oxide ) ( PEO ) , poly ( vinyl alcohol ) 25 starches such as corn starch , potato starch , pre - gelatinized 
( PVA ) , hydroxypropyl methylcellulose ( HPMC ) , ethylcel - and modified starches thereof , sweeteners , clays , bentonite , 
lulose ( EC ) , hydroxyethylcellulose ( HEC ) , sodium car - microcrystalline cellulose ( e . g . , AvicelTM ) , carboxymethyl 
boxymethyl - cellulose ( CMC ) , dimethylaminoethyl meth - cellulose calcium , croscarmellose sodium , alginic acid , 
acrylate - methacrylic acid ester copolymer , ethylacrylate - sodium alginate , cellulose polyacrilin potassium ( e . g . , 
methylmethacrylate copolymer ( GA - MMA ) , C - 5 or 60 30 AMBERLITETM ) , alginates , sodium starch glycolate , gums , 
SH - 50 ( Shin - Etsu Chemical Corp . ) , cellulose acetate phtha agar , guar , locust bean , karaya , pectin , tragacanth , crospovi 
late ( CAP ) , cellulose acetate trimelletate ( CAT ) , poly ( vinyl done and other materials known to one of ordinary skill in 
acetate ) phthalate ( PVAP ) , hydroxypropylmethylcellulose the art . A superdisintegrant is a rapidly acting disintegrant . 
phthalate ( HPMCP ) , poly ( methacrylate ethylacrylate ) ( 1 : 1 ) Exemplary superdisintegrants include crospovidone and low 
copolymer ( MA - EA ) , poly ( methacrylate methylmethacry - 35 substituted HPC . 
late ) ( 1 : 1 ) copolymer ( MA - MMA ) , poly ( methacrylate meth - Suitable surfactants include Polysorbate 80 , sorbitan 
ylmethacrylate ) ( 1 : 2 ) copolymer , EUDRAGIT L - 30 - DTM monooleate , sodium lauryl sulfate or others . Soaps and 
( MA - EA , 1 : 1 ) , EUDRAGIT L - 100 - 55TM ( MA - EA , 1 : 1 ) , synthetic detergents may be employed as surfactants . Suit 
hydroxypropylmethylcellulose acetate succinate ( HPM - able soaps include fatty acid alkali metal , ammonium , and 
CAS ) , COATERICTM ( PVAP ) , AQUATERICTM ( CAP ) , and 40 triethanolamine salts . Suitable detergents include cationic 
AQUACOATTM ( HPMCAS ) , polycaprolactone , starches , detergents , for example , dimethyl dialkyl ammonium 
pectins ; polysaccharides such as tragacanth , gum arabic , halides , alkyl pyridinium halides , and alkylamine acetates ; 
guar gum , and xanthan gum . anionic detergents , for example , alkyl , aryl and olefin sul 
The stabilizing and non - solubilizing carrier may also fonates , alkyl , olefin , ether and monoglyceride sulfates , and 
contain various functional excipients , such as : hydrophilic 45 sulfosuccinates ; nonionic detergents , for example , fatty 
polymer , antioxidant , super - disintegrant , surfactant includ - amine oxides , fatty acid alkanolamides , and poly ( oxyethyl 
ing amphiphilic molecules , wetting agent , stabilizing agent , ene ) - block - poly ( oxypropylene ) copolymers ; and ampho 
retardant , similar functional excipient , or combination teric detergents , for example , alkyl B - aminopropionates and 
thereof , and plasticizers including citrate esters , polyethyl - 2 - alkylimidazoline quaternary ammonium salts ; and mix 
ene glycols , PG , triacetin , diethylphthalate , castor oil , and 50 tures thereof . 
others known to those or ordinary skill in the art . Extruded Wetting agent is an agent that decreases the surface 
material may also include acidifying agent , adsorbent , alka tension of a liquid . Wetting agents would include alcohols , 
lizing agent , buffering agent , colorant , flavorant , sweetening glycerin , proteins , peptides water miscible solvents such as 
agent , diluent , opaquant , complexing agent , fragrance , pre glycols , hydrophilic polymers Polysorbate 80 , sorbitan 
servative or a combination thereof . 55 monooleate , sodium lauryl sulfate , fatty acid alkali metal , 
Exemplary hydrophilic polymers which can be a primary ammonium , and triethanolamine salts , dimethyl dialkyl 
or secondary polymeric carrier that can be included in the ammonium halides , alkyl pyridinium halides , and alkylam 
composition include poly ( vinyl alcohol ) ( PVA ) , polyethyl ine acetates ; anionic detergents , for example , alkyl , aryl and 
ene - polypropylene glycol ( e . g . POLOXAMERTM ) , car - olefin sulfonates , alkyl , olefin , ether and monoglyceride 
bomer , polycarbophil , or chitosan . The “ hydrophilic poly - 60 sulfates , and sulfosuccinates ; nonionic detergents , for 
mers ” of the present invention include one or more of example , fatty amine oxides , fatty acid alkanolamides , and 
hydroxypropyl methylcellulose , carboxymethylcellulose , poly ( oxyethylene ) - block - poly ( oxypropylene ) copolymers ; 
hydroxypropyl cellulose , hydroxyethyl cellulose , methylcel and amphoteric detergents , for example , alkyl ß - aminopro 
lulose , natural gums such as gum guar , gum acacia , gum p ionates and 2 - alkylimidazoline quaternary ammonium 
tragacanth , or gum xanthan , and povidone . “ Hydrophilic 65 salts ; and mixtures thereof . 
polymers ” also include polyethylene oxide , sodium car - For the purpose of the present invention , stabilizing 
boxymethylcellulose , hydroxyethyl methyl cellulose , agents are polymers and excipients that do not solubilize the 
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drug particles preferably agents with high melting points or begins within no more than about 2 minutes after adminis 
glass transition temperatures and / or agents with no or mini - tration . An immediate release does not exhibit a significant 
mal affinity for the active . The excipients restrict the mobil delay in the release of drug . 
ity of drug particles within the carrier thereby reducing By “ rapid release ” is meant a release of an active agent to 
particle aggregation and agglomeration on processing and 5 an environment over a period of 1 - 59 minutes or 0 . 1 minute 
storage . Such excipients include cellulosic polymers includ ch excipients include cellulosic polymers includ - to three hours once release has begun and release can begin 
ing HPMC , HPC , methylcellulose ; polyvinyl alcohol , poly within a few minutes after administration or after expiration 
vinylpyrrolidone , polyvinylpyrrolidone - co - vinyl acetate and of a delay period ( lag time ) after administration . 
others known to those of ordinary skill in the art . As used herein , the term “ extended release " profile 
Retardants are agents that are insoluble or slightly soluble 1 10 assumes the definition as widely recognized in the art of pharmaceutical sciences . An extended release dosage form polymers with a Tg above 45° C . , more preferably above 50° 
C . before being plasticized by other agents in the formula will release drug at substantially constant rate over an extended period of time or a substantially constant amount tion including other polymers and other excipients needed of drug will be released incrementally over an extended 
Tor processing . The excipients include waxes , acrylics , cel - 15 period of time . An extended release tablet generally effects for processing . The excipients include waxes , acrylics , cel - 15 peric 
lulosics , lipids , proteins , glycols , and the like . at least a two - fold reduction in dosing frequency as com 
Under the conditions of the hot - melt extrusion process of pared to the drug presented in a conventional dosage form 
the invention , the fine drug - containing particles are deaggre - ( e . g . , a solution or rapid releasing conventional solid dosage 
gated and homogenously dispersed such that they exist forms ) . 
within the carrier as individual particles having a median 20 By " controlled release ” is meant a release of an active 
particle diameter size range of less than one hundred agent to an environment over a period of about eight hours 
microns , or less than twenty microns , and or less than five up to about 12 hours , 16 hours , 18 hours , 20 hours , a day , or 
microns . The extrusion process may be performed once , or more than a day . By “ sustained release ” is meant an 
several times in series to further deaggregate and disperse extended release of an active agent to maintain a constant 
the drug particles . 25 drug level in the blood or target tissue of a subject to which 
The resulting product can be produced in the form of the device is administered . The term “ controlled release ” , as 
tubes , strands , cylinders , or films , and can be further pro regards to drug release , includes the terms “ extended 
cessed to fine powders , granules , pellets , spheres , or tablets release ” , “ prolonged release ” , “ sustained release " , or " slow 
that are intended for oral delivery . The resulting product can release ” , as these terms are used in the pharmaceutical 
also be formulated for transdermal , transmucosal , rectal , atal 30 sciences . An controlled release can begin within a few 
pulmonary , nasal , vaginal , ocular , or otic drug delivery as minutes after administration or after expiration of a delay period ( lag time ) after administration . well as an implantable drug delivery device . A slow release dosage form is one that provides a slow The solid dosage formulations of the invention can rate of release of drug so that drug is released slowly and assume any shape or form known in the art of pharmaceu 35 approximately continuously over a period of 3 hr , 6 hr , 12 hr , tical sciences . The dosage form can be a sphere , tablet , bar , 18 hr , a day , 2 or more days , a week , or 2 or more weeks , 
plate , paraboloid of revolution , ellipsoid of revolution or for examp 
other one known to those of ordinary skill in the art . The A timed release dosage form is one that begins to release 
solid dosage form can also include surface markings , cut - drug after a predetermined period of time as measured from 
tings , grooves , letters and / or numerals for the purposes of 40 the moment of initial exposure to the environment of use . 
decoration , identification and / or other purposes . A targeted release dosage form generally refers to an oral 
The resulting composition is characterized by the sub - dosage form that designed to deliver drug to a particular 
stantial absence of agglomerated or aggregated fine drug - portion of the gastrointestinal tract of a subject . An exem 
containing particles after processing and after storage for plary targeted dosage form is an enteric dosage form that 
extended times and at various temperature and humidity 45 delivers a drug into the middle to lower intestinal tract but 
conditions . not into the stomach or mouth of the subject . Other targeted 
The carrier and / or the additional functional excipients dosage forms can delivery to other sections of the gastro 
may be formulated as to provide a predetermined approxi - intestinal tract such as the stomach , jejunum , ileum , duode 
mate release profile under predetermined conditions . The num , cecum , large intestine , small intestine , colon , or rec 
drug can be released according to an immediate , fast melt , 50 tum . 
rapid , sustained , controlled , slow , pulsatile or extended , and By " delayed release ” is meant that initial release of drug 
optionally delayed , targeted or timed drug release profile . occurs after expiration of an approximate delay ( or lag ) 
The pharmaceutical composition may deliver one or more period . For example , if release of drug from an extended 
active agents in an extended release manner , and mecha release composition is delayed two hours , then release of 
nisms employed for such delivery can include active agent 55 drug from begins at about two hours after administration of 
release that is pH - dependent or pH - independent ; diffusion or the composition , or dosage form , to a subject . In general , a 
dissolution controlled ; pseudo - zero order ( approximates delayed release is opposite an immediate release , wherein 
zero - order release ) , zero - order , pseudo - first order ( approxi - release of drug begins after no more than a few minutes after 
mates first - order release ) , or first - order ; or slow , delayed , administration . Accordingly , the drug release profile from a 
timed or sustained release or otherwise controlled release . 60 particular composition can be a delayed - extended release or 
The release profile for the active agent can also be sigmoidal a delayed - rapid release . A " delayed - extended ” release pro 
in shape , wherein the release profile comprises an initial file is one wherein extended release of drug begins after 
slow release rate , followed by a middle faster release rate expiration of an initial delay period . A “ delayed - rapid ” 
and a final slow release rate of active agent . release profile is one wherein rapid release of drug begins 
By " immediate release ” is meant a release of an active 65 after expiration of an initial delay period . 
agent to an environment over a period of seconds to no more A pulsatile release dosage form is one that provides pulses 
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low concentration troughs . A pulsatile profile containing two 75 % relative humidity . This figure represents the prevention 
peaks may be described as “ bimodal ” . or inhibition of particle aggregation or agglomeration on 
A pseudo - first order release profile is one that approxi storage by the stabilizing carrier . 
mates a first order release profile . A first order release profile Visual inspection of exemplary compositions No . 1 - No . 
characterizes the release profile of a dosage form that 5 10 ( Example 1 ) of the invention is conducted by SEM 
releases a constant percentage of an initial drug charge per according to Example 2 or with the unaided eye . Some of the 
unit time . results are summarized below . Visual inspection of the A pseudo - zero order release profile is one that approxi composition of the invention was conducted by SEM and the mates a zero - order release profile . A zero - order release unaided eye . profile characterizes the release profile of a dosage form that 10 
releases a constant amount of drug per unit time . 
The resulting product may also be formulated to exhibit No . Transparency Surface Texture Color 
enhanced dissolution rate of a formulated poorly water 
soluble drug . Transparent Smooth Yellow Slightly textured Opaque White Due to the deaggregation of fine particles on processing to 15 Translucent Textured Light form primary particles that are stabilized by the carrier yellow 
system , the composition or dosage form will generally Opaque Textured 
possess a substantially stable release profile during storage . Translucent Coarse Light 
Yellow to opaque As used herein , the term “ stable release profile ” refers to a Opaque Coarse White dosage form that provides approximately the same release 20 Opaque Smooth 
profile for a drug over the period of time during which the Opaque Slightly textured White 
dosage form is stored . More specifically , a stable release Transparent Smooth Yellow 
profile is one wherein a dosage form provides a first release Opaque White Slightly textured 
profile after being stored a short first period of time under a 
first set of conditions and provides a second release profile 25 The opaque and white appearance of extrudates contain 
after being stored a longer second period of time under the ing itraconazole signifies that itraconazole is not solubilized 
same first set of conditions such that the first and second by the carrier system when hot - melt extruded at 100° C . 
release profiles vary by no more than + 10 % . Therefore , an Being that this opacity was seen for each formulation , it can 
unstable release profile is one wherein the first and second be concluded that each of the functional additives did not 
release profiles are not approximately the same , i . e . vary by 30 influence the solubility of itraconazole in PEO . For each of 
more than + 10 % . the other non - active formulations , the color and texture was 
An example of a composition or formulation having a seen to be homogenous , indicating that each of the additives 
stable release profile follows . Two tablets having the same are compatible with PEO when hot - melt extruded at 100° C . 
formulation are made . The first tablet is stored for one day The appearance of a non - homogeneous color distribution or 
under a first set of conditions , and the second tablet is stored 35 surface texture would generally signify aggregation and 
for four months under the same first set of conditions . The indicate immiscibility of the additive with PEO . 
release profile of the first tablet is determined after the single FIGS . 2a - 2c depict SEM micrographs of micronized 
day of storage and the release profile of the second tablet is itraconazole ( ITZ ) ( FIG . 2a ) having an average particle size 
determined after the four months of storage . If the release of 2 . 5 microns , hot - melt extruded PEO ( FIG . 2b ) having an 
profile of the first tablet is approximately the same as the 40 average molecular weight of about 200 , 000 , and hot - melt 
release profile of the second tablet , then the tablet / film extruded formulation No . 2 ( FIG . 2c ) . Initially , the ITZ 
formulation is considered to have a stable release profile . shows some aggregation and / or agglomeration prior to hot 
Another example of a composition or formulation having melt extrusion . However , during hot - melt extrusion the 
a stable release profile follows . Tablets A and B , each particles are deagglomerated and / or deaggregated and not 
comprising a film composition according to the invention , 45 dissolved by the carrier . 
are made , and Tablets C and D , each comprising a film FIG . 2d depicts a DSC thermogram for hot - melt extruded 
composition not according to the invention , are made . PEO and a composition made according to formula No . 2 . 
Tablets A and C are each stored for one day under a first set The melting point of crystalline itraconazole is known to be 
of conditions , and tablets B and D are each stored for three about 165° C . The drug - containing composition shows a 
months under the same first set of conditions . The release 50 melting point of 127 . 72° C . for ITZ , signifying the tempera 
profile for each of tablets A and C is determined after the ture at which crystalline itraconazole is solubilized in PEO . 
single day of storage and designated release profiles A and This indicates that ITZ is present in its crystalline form in the 
C , respectively . The release profile for each of tablet B and extrudate , and it therefore is not solubilized by PEO when 
D is determined after the three months of storage and hot - melt extruded at 100° C . It is thus shown that PEO is a 
designated release profiles B and D , respectively . The dif - 55 suitable thermal binder for a stabilizing and non - solubilizing 
ferences between release profiles A and B are quantified as carrier system for fine particles of itraconazole when hot 
are the differences between release profiles C and D . If the melt extruded at 100° C . 
difference between the release profiles A and B is less than FIGS . 3a - 3c depict SEM micrographs of HPMC E15 
the difference between release profiles C and D , tablets A ( FIG . 3a ) having an average viscosity of 5 cPs as a 2 % w 
and B are understood to provide a stable or more stable 60 solution with water , hot - melt extruded PEO and HPMC 
release profile . ( FIG . 3b ) according to formula No . 3 , and hot - melt extruded 
FIG . la depicts a conceptual cross - sectional front eleva formulation No . 4 ( FIG . 3c ) . It is shown in FIG . 3b that 
tion of an exemplary hot - melt extruded composition accord HPMC is reduced in particle size and dispersed in a crys 
ing to the invention illustrating individualized fine drug talline form throughout the PEO matrix indicating the mis 
particles homogenously dispersed in a stabilizing and non - 65 cibility of HPMC with PEO when hot - melt extruded at 100° 
solubilizing carrier system . FIG . 1b illustrates the same C . When the ITZ is added , the extrudate now comprises 
formulation after storage in sealed containers at 40° C . and readily identifiable particles of ITZ indicating that it is 
17 
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deaggregated during hot - melt extrusion and that the HPMCI carrier phase includes one or more components that solubi 
PEO carrier does not solubilize the ITZ during extrusion . In lize a portion of the drug hot - melt extrusion include those 
fact , the particles are deagglomerated and / or deaggregated components in amounts insufficient to solubilize a substan 
by the carrier during hot - melt extrusion . tial amount of the drug during hot - melt extrusion . For 
FIG . 3d includes a DSC thermogram for the formulations 5 example , such components are present in an amount such 
of FIGS . 35 and 3c . The drug - containing composition shows that less than 10 % by wt . , less than 5 % by wt . or less than 
a melting point of 127 . 33° C . for ITZ meaning that ITZ is 1 % by wt . of the drug can solubilize during hot - melt 
present in its crystalline form in the extrudate . This further extrusion . 
demonstrates that ITZ is not solubilized by the PEO / HPMC FIGS . 6a - 6c depict SEM micrographs of poloxamer 407 
carrier . 10 ( FIG . 6a ) having an average molecular weight of about 
FIGS . 4a - 4c depict SEM micrographs of PVA ( FIG . 4a ) 9 , 840 to 14 , 600 g / mol , hot - melt extruded PEO and polox 
having an average molecular weight of about 30 to 200 , 000 amer ( FIG . 6b ) according to Formulation No . 9 , and hot 
g / mol , hot - melt extruded PEO and PVA ( FIG . 4b ) according melt extruded formulation No . 10 ( FIG . 6c ) . The poloxamer 
to Formulation No . 5 , and hot - melt extruded formulation and PEO form a substantially homogeneous extrudate indi 
No . 6 ( FIG . 4c ) . It is shown in FIG . 4b that HPMC is reduced 15 cating complete miscibility when hot - melt extruded at 100° 
in particle size and dispersed in a crystalline form through C . When the ITZ is added , the extrudate now comprises 
out the PEO matrix indicating the miscibility of PVA with readily identifiable particles of ITZ indicating that it is 
PEO when hot - melt extruded at 100° C . When the ITZ is deaggregated during hot - melt extrusion and the PEO / polox 
added , the extrudate now comprises readily identifiable amer carrier does not solubilize the ITZ during extrusion . 
particles of ITZ indicating that it is deaggregated during 20 Again , the particles are deagglomerated and / or deaggregated 
hot - melt extrusion and not solubilized by the PEO / PVA by the carrier during hot - melt extrusion . 
carrier during extrusion . As above , the particles are FIG . 6d includes a DSC thermogram for formulations of 
deagglomerated and / or deaggregated by the carrier during FIGS . 6b and 6c . The drug - containing composition shows a 
hot - melt extrusion . melting point of 124 . 18° C . for ITZ , again indicating that 
FIG . 4d includes a DSC thermogram for formulations of 25 ITZ is present in its crystalline form in the extrudate , and is 
FIGS . 4b and 4c . The drug - containing composition shows a therefore not solubilized by the carrier system . The slight 
melting point of 125 . 99° C . for ITZ , again indicating that depression of the melting point indicates that a small portion 
ITZ is present in its crystalline form in the extrudate and is of the crystalline ITZ is solubilized by the carrier system 
therefore not solubilized by the carrier system . The slight below 127° C . Most of this amount of dissolved ITZ is 
depression of the melting point indicates that a small portion 30 solubilized in a narrow temperature range near the solubi 
of the crystalline ITZ is solubilized by the carrier system lization point in this carrier system ( 124 . 18° C . ) . Therefore , 
below 127° C . A majority of this amount of dissolved ITZ it can be concluded that only a negligible amount , i . e less 
is solubilized in a narrow temperature range near the solu - than 5 w of the loaded ITZ is solubilized by the poloxamer 
bilization point in this carrier system ( 125 . 99° C . ) . There in the formulation during hot - melt extrusion at 100° C . 
fore , it can be concluded that only a negligible amount , i . e 35 The above - described results indicate that the hot - melt 
less than 5 % by wt . of the loaded ITZ is solubilized by the extrudates composed of PEO and poloxamer formed a 
PVA in the formulation during hot - melt extrusion at 100° C . homogeneous polymer matrix when melt extruded at 100° 
Increasing the ratio of PVA to ITZ above one to one may C . Further , compositions containing HPMC , PVA , or SLS 
cause a greater extent of ITZ to become solubilized in the were observed to have homogenously dispersed particles 
carrier system . 40 throughout the PEO matrix following melt extrusion . 
FIGS . 5a - 5c depict SEM micrographs of sodium lauryl Upon visual inspection it was determined that the addition 
sulfate ( SLS ) ( FIG . 5a ) , hot - melt extruded PEO and SLS of itraconazole to each of the formulations produced opaque 
( FIG . 5b ) according to Formulation No . 7 , and hot - melt extrudates when melt extruded at 100° C . SEM revealed that 
extruded formulation No . 8 ( FIG . 5c ) . It is shown in FIG . 5b crystalline itraconazole was dispersed as discrete particles 
that SLS is reduced in particle size and dispersed throughout 45 throughout the polymeric matrix following extrusion for 
the PEO matrix indicating the miscibility of SLS with PEO each composition . 
when hot - melt extruded at 100° C . When the ITZ is added , DSC analysis of the compositions indicated that , at a 
the extrudate now comprises readily identifiable particles of loading of 10 % ( w / w ) , itraconazole it has a melting point of 
ITZ indicating that it is deaggregated during hot - melt extru - approximately 127° C . after melt extrusion with PEO at 
sion and the PEO / SLS carrier does not solubilize the ITZ 50 100° C . Moreover , approximately the same melting point for 
during extrusion . Again , the particles are deagglomerated itraconazole was also observed when any one of the chosen 
and / or deaggregated by the carrier during hot - melt extru - polymers or surfactants was incorporated into the extruded 
formulation . 
FIG . 5d includes a DSC thermogram for formulations of Under the conditions evaluated , itraconazole is substan 
FIGS . 5b and 5c . The drug - containing composition shows a 55 tially insoluble in PEO when extruded at 100° C . as con 
melting point of 124 . 55° C . for ITZ , again indicating that firmed by SEM and DSC . In addition , the solubility of 
ITZ is present in its crystalline form in the extrudate and is itraconazole in PEO when melt extruded at 100° C . was not 
therefore not solubilized by the carrier system . The slight influenced by the inclusion of HPMC , Poloxamer 407 , PVA , 
depression of the melting point indicates that a small portion or SLS to the formulation . 
of the crystalline ITZ is solubilized by the carrier system 60 The ability of the carrier to provide a substantially stable 
below 127° C . Most of this amount of dissolved ITZ is release profile after storage of a composition according to 
solubilized in a narrow temperature range near the solubi - the invention was determined by conducting dissolution 
lization point in this carrier system ( 124 . 55° C . ) . Therefore , profile assays for various controls and sample . FIG . 7 
it can be concluded that only a negligible amount , i . e less depicts exemplary drug release profiles for the composition 
than 5 % by wt . of the loaded ITZ is solubilized by the SLS 65 of Example 1 . The first line ( diamond markers ) depicts the 
in the formulation during hot - melt extrusion at 100° C . release profile for danazol within one day of preparation of 
Accordingly , embodiments of the invention wherein the the composition . The second line ( square markers ) depicts 
sion . 
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the release profile for danazol following 3 months storage in labile to an extent that recrystallization of the drug occurs . 
sealed containers at 40° C . and 75 % relative humidity . The Therefore , it is important to formulate amorphous drug 
drug release profile remains substantially the same . particles to include such excipients as polymers with high 
The term “ hot - melt extrusion ” is used herein to describe glass transition temperatures so that the maximum extrusion 
a process whereby an excipient blend is heated to a molten 5 temperature is in a range above the softening temperatures 
state and subsequently forced through an orifice where the of common thermal binders . Thus , the temperature at which 
extruded product is formed into its final shape in which it is the active compound dissolves into a carrier formulation or 
solidified upon cooling . The blend is conveyed through at which amorphous fine drug particles begin to recrystallize 
various heating zones typically by a screw mechanism . The must be determined experimentally before deciding the most 
screw or screws are rotated by a variable speed motor inside 10 appropriate extrusion conditions . This can be done by DSC 
a cylindrical barrel where only a small gap exists between analysis for varying ratios of active particles to carrier and 
the outside diameter of the screw and the inside diameter of noting the temperature of the thermal event associated with 
the barrel . In this conformation , high shear is created at the the drug , i . e . the endothermic event for the melting point of 
barrel wall and between the screw fights by which the crystalline drug and the exothermic event for the recrystal 
various components of the powder blend are well mixed and 15 lization of amorphous drug . When extruding compositions 
deaggregated . The hot - melt extrusion equipment is typically containing amorphous drug particles , the maximum extru 
a single or twin - screw apparatus , but can be composed of sion temperature must be below the temperature of recrys 
more than two screw elements . A typical hot - melt extrusion tallization , approximately 10° to 20° C . When extruding 
apparatus contains a mixing / conveying zone , a heating compositions containing crystalline drug particles , the maxi 
melting zone , and a pumping zone in succession up to the 20 mum extrusion temperature must be at least 10° C . below the 
orifice . In the mixing / conveying zone , the powder blends are melting point . 
mixed and aggregates are reduced to primary particles by the It follows from the discussion above that for a carrier 
shear force between the screw elements and the barrel . In the system to be viable with a particular form of fine drug 
heating / melting zone , the temperature is at or above the particles it must be hot - melt extrudable at temperatures 
melting point or glass transition temperature of the thermal 25 below the maximum extrusion temperature of the active . If 
binder or binders in the blend such that the conveying solids the carrier system does not become molten at the highest 
become molten as they pass through the zone . A thermal processing temperatures , an acceptable extruded product 
binder in this context describes an inert excipient , typically will not be formed . Therefore , the most appropriate extru 
a polymer , that is sufficiently solid at ambient temperature , sion temperature is that which makes the carrier system 
but becomes molten or semi -liquid when exposed to 30 molten and is below the solubilization and / or recrystalliza 
elevated heat or pressure . The thermal binder acts as the tion temperature of the active particles . 
matrix in which the active or actives and other functional Other process variables such as feed rate and screw speed 
ingredients are dispersed , or the adhesive with which they are optimized to provide adequate shear and mixing so that 
are bound such that a continuous composite is formed at the the fine drug particles are deaggregated and well dispersed 
outlet orifice . Once in a molten state , the homogenized blend 35 as primary particles in the matrix of the carrier . The effect of 
is pumped to the orifice through another heating zone that feed rate and screw speed on such dependent variables as the 
maintains the molten state of the blend . At the orifice , the level of shear and mixing inside the extruder depends 
molten blend can be formed into strands , cylinders or films . heavily on the design of the equipment and namely the screw 
The extrudate that exits is then solidified typically by an elements . Generally , increasing the screw speed will 
air - cooling cooling process . Once solidified , the extrudate 40 increase the shear forces between the screw element and the 
may then be further processed to form pellets , spheres , fine barrel wall , thereby allowing for more rigorous mixing and 
powder , tablets , and the like . An example of a single screw a greater extent of particle deaggregation . Decreasing the 
apparatus similar to the description above is the Randcastle feed rate ( non - flood feeding ) will generally allow for more 
Microtruder , model RCP - 0750 . complete mixing and particle deaggregation due a reduction 
For the proposed invention , the active substance or sub - 45 in the amount of material within the extruder . For the present 
stances include fine drug particles that are produced by a invention , there should be sufficient shearing to deaggregate 
mechanical milling , a solvent based phase separation , or a the fine drug particles and homogenously disperse the result 
rapid freezing process . These fine particles will enter the ing primary particles throughout the carrier matrix . To 
feeding zone of the extruder as aggregated particles due to determine adequate shearing , the extruded product can be 
strong interparticle cohesive forces . These fine particles will 50 examined by SEM to observe a typical particle size and 
be deaggregated and dispersed in the carrier system by the degree of particle separation . If unsatisfactory deaggregation 
high shear forces that exist between the screw elements and or dispersion is seen , the feed rate may be reduced and / or 
the barrel . Thus , the process serves as a means of reducing screw speed increased to increase the vigor of the mixing . It 
fine particle aggregates to primary particles such that the full may also be beneficial to reprocess the material by hot - melt 
benefit of particle size reduction is realized . 55 extrusion one or more times to achieve a homogenous 
Temperature is an important process variable to consider deaggregated dispersion . 
for the proposed invention . To maintain the integrity of the Consideration should be given to the manner in which the 
fine drug particles , the blend is extruded at least ten degrees components of a formulation are fed to the extruder . In some 
Celsius or more below the temperature at which the active embodiment , all formulation components are blended 
substance dissolves into the carrier at the extruded ratio . For 60 together to form a blended mixture before being fed to the 
example , itraconazole is solubilized by PEO at approxi - extruder . This can be done by any traditional mixing or 
mately 127° C . in a nine to one ratio of PEO to itraconazole . blending technique . Alternatively , formulation components 
Therefore , when extruding fine particles of itraconazole in a may be fed individually if done simultaneously , and given 
PEO carrier at a nine to one ratio , the greatest extrusion that there is adequate mixing of the formulation components 
temperature must be at most 117° C . For amorphous fine 65 in the mixing / conveying zone of the extruder . 
drug particles , this maximum extrusion temperature is the desiccant can be used to aid in storing a formulation 
temperature at which the stabilizing excipients become according to the invention in order to help maintain a stable 
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release profile . Suitable desiccants include sodium sulfate , mixture . The peaks noted with the red arrows are peaks 
calcium sulfate , magnesium sulfate , sodium hydroxide , associated with crystalline ITZ as are seen with the bulk 
sodium bicarbonate , clay , vermiculite , paper , activated alu drug and the physical mixture , yet not seen in Example 9 or 
mina , zeolite , calcium chloride , molecular sieve , or anhy 10 . This figure serves as supplemental analysis to DSC in its 
drous chemicals . Accordingly , the method of invention for 5 demonstration that the amorphous nature of the PVP - stabi 
stabilizing the release profile of a film - coated dosage form lized amorphous ITZ particles is not altered by hot - melt 
can comprise the step of including a desiccant in the extrusion with a non - solubilizing carrier system when extru 
container in which the dosage form is stored . In some cases s ion temperatures are sufficiently below the T , the particle 
a desiccant is needed if the carrier materials of the drug are composite . 
hygroscopic since moisture may affect the physical stability 10 FIGS . 11a - 11d depict SEM images obtained according to 
of the primary crystalline or amorphous particles . Example 2 for samples prepared according to Example 9 
The influence of storage time , temperature and relative ( FIG . 11a ) , a Poloxamer : PEO ( 7 : 3 ) placebo extrudate ( FIG . 
humidity upon the release profiles of composition made 11b ) , and samples prepared according Example 10 ( FIGS . 
herein is depicted in FIG . 8 . FIG . 8 compares , before and 110 and 11d ) . From a comparison of the SEM images , it can 
after storage , the release profiles of danazol dispersions 15 be seen that the PVP - stabilized amorphous ITZ particles are 
made according to the proposed invention with an amor - not molten during hot - melt extrusion and are dispersed 
phous solid solution of danazol whereby amorphous drug within the polymer matrix as discernable , individualized 
particles are formed in - situ during hot - melt extrusion . Lines particles by the hot - melt extrusion process . 
on FIG . 8 denoted by triangular and diamond shaped mark - FIG . 12 depicts the results of a comparative dissolution 
ers represent the two formulations prior to storage , both 20 test obtained according to Example 12 for samples made 
showing similar release profiles . Lines on FIG . 8 denoted by according to Example 10 , samples made according to 
square and x shaped markers show the dissolution profile of Example 9 , and bulk ITZ . The figure demonstrates that the 
the two formulations after three month storage in sealed dissolution rate of ITZ is faster in the case of the extrudates 
containers at 40° C . and 75 % . It can be seen that the than the amorphous particles alone with 90 % drug release in 
dissolution rate of the danazol dispersion produced by 25 10 minutes compared to 62 % , respectively . Both the extru 
in - situ formation of amorphous danazol particles is signifi - dates and the amorphous particles exhibited substantially 
cantly decreased after storage . This is the result of agglom - faster dissolution rates over the bulk ITZ as the bulk ITZ 
eration and recrystallization of amorphous danazol particles showed less than 1 % dissolved in 10 minutes . This figure 
due to the perturbations during storage . This decrease is not demonstrates that hot - melt extrusion of PVP - stabilized 
seen in the case of the formulation produced according to the 30 amorphous ITZ particles in a hydrophilic carrier improves 
proposed invention because fine drug particles of danazol the dissolution properties of the particles . This improvement 
are stabilized against recrystallization by formulation with a is the result of increased surface area and enhanced wetta 
stabilizing excipient during the production of the particles . bility of the drug particles by deaggregation and dispersion 
Additionally aggregation of fine danazol particles is pre of the particles into a hydrophilic carrier via the hot - melt 
vented by the stabilizing nature of the carrier system . Thus , 35 extrusion process . The substantial improvement of the extru 
the physical stability of the fine drug particles is maintained dates and the amorphous particles alone over the bulk ITZ 
and hence the dissolution profile is maintained unchanged demonstrates the benefit of formulating ITZ in the amor 
with storage . phous state for achieving rapid dissolution . 
FIG . 9 depicts DSC thermograms obtained according to FIG . 13 depicts comparative dissolution profiles for 
Example 3 of PVP - stabilized amorphous ITZ particles ( Ex - 40 samples made according to Example 9 and samples made 
ample 9 ) , extrudates containing PVP - stabilized amorphous according to Example 10 before and after storage according 
ITZ ( Example 10 ) , a physical mixture of crystalline ITZ to Example 4 at conditions of 40° C . and 75 % relative 
with the excipient components of Examples 9 and 10 , PVP humidity in aluminum induction sealed high density poly 
K25 , and bulk crystalline ITZ . The DSC thermograms ethylene bottles for a period of two weeks . The dissolution 
indicate that the PVP - stabilized ITZ particles are substan - 45 profile of the hot - melt extruded amorphous ITZ particles is 
tially amorphous compared to bulk ITZ as seen by the stable on storage for 2 weeks , whereas the dissolution profile 
complete absence of an endothermic event at 165° C . that is of the amorphous particles alone is unstable as it was 
associated with the melting of crystalline ITZ . The thermo - substantially decreased on storage . This figure demonstrates 
grams also demonstrate that the amorphous nature of the the effect that hot - melt extruding the amorphous ITZ par 
PVP - stabilized ITZ particles is maintained during the melt 50 ticles in a stabilizing carrier system has upon dissolution 
extrusion process as seen by the absence of an endothermic profile stability . The stabilizing carrier system protects the 
event at approximately 160° C . as is seen with the physical drug particles from ambient moisture absorption that would 
mixture containing crystalline ITZ . This figure demonstrates otherwise lead to particle aggregation and recrystallization 
that the amorphous nature of the PVP - stabilized amorphous of the amorphous drug . The aforementioned effects of 
ITZ particles is not altered by hot hot - melt extrusion with a 55 ambient moisture absorption are clearly seen with the 
non - solubilizing carrier system when extrusion temperatures decrease in dissolution rate of the amorphous ITZ particles 
are well below the T . ( glass transition temperature ) the after 2 weeks storage . 
particle composite . FIG . 14 depicts DSC thermograms obtained according to 
FIG . 10 depicts X - ray diffraction patterns obtained accord Example 3 for samples produced according to Example 13 , 
ing to Example 11 for poloxamer 407 : PEO ( 7 : 3 ) placebo 60 samples produced according to Example 14 , a physical 
extrudate , a physical mixture of crystalline ITZ with the mixture of crystalline CBM with the excipient components 
excipient components of Examples 9 and 10 , extrudates of examples 13 and 14 , and PVP K25 . The DSC thermo 
containing PVP - stabilized amorphous ITZ ( Example 10 ) , grams indicate that the PVP - stabilized CBM particles are 
bulk ITZ , and PVP - stabilized amorphous ITZ ( Example 9 ) . substantially amorphous as seen by the complete absence of 
The results show a substantially amorphous content of drug 65 the endothermic event at 190° C . that is associated with the 
for both Example 9 and Example 10 when compared to the melting of crystalline CBM . The thermograms also indicate 
control bulk crystalline itraconazole sample and physical that the morphology of PVP - stabilized amorphous CBM 
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particles was not altered by the hot - melt extrusion process as extruded amorphous CBM particles is stable following 2 
seen by the absence of the broad endothermic event in the weeks of storage , whereas the dissolution profile of the 
range of 170 to 190° C . that is associated with the melting amorphous particles alone is unstable as it was substantially 
of crystalline CBM in the presence of the other excipients as decreased on storage . This figure demonstrates the effect of 
seen with the physical mixture . This figure therefore dem - 5 hot - melt extruding the amorphous CBM particles in a sta 
onstrates that the morphology of the PVP - stabilized amor - bilizing carrier system that protects them from ambient 
phous CBM particles is not altered by hot - melt extrusion moisture absorption that leads to particle aggregation and 
with a non - solubilizing carrier formulation when extrusion recrystallization of the amorphous drug . The aforemen 
temperature is sufficiently lower than the To of the particle tioned effects of ambient moisture absorption are clearly 
composite . 10 seen by the decrease in dissolution rate of the amorphous 
FIG . 15 depicts X - ray diffraction patterns obtained accord CBM particles after 2 weeks storage . 
ing to Example 11 for poloxamer 407 : PEO ( 7 : 3 ) placebo FIG . 19 depicts DSC thermograms obtained according to 
extrudate , a physical mixture of crystalline CBM with the Example 3 for samples produced according to Example 15 , 
excipient components of Examples 13 and 14 , samples HPMC E3 , samples produced according to Example 16 , a 
produced according to Example 14 , samples produced 15 physical mixture of crystalline KCZ with the excipient 
according to Example 13 , and bulk CBM . The data indicate components of Examples 15 and 16 , and bulk ketoconazole . 
a substantially amorphous content of drug for both Example The DSC thermograms indicate that the HPMC - stabilized 
13 and Example 14 when compared to the control bulk KCZ particles are substantially amorphous compared to bulk 
crystalline itraconazole sample and physical mixture . The ketoconazole as seen by the complete absence of the endo 
peaks noted with the arrows are peaks associated with 20 thermic event at 151° C . associated with the melting of 
crystalline CBM as are seen with the bulk drug and the crystalline KCZ . The thermograms also indicate that the 
physical mixture , yet not seen with the sample of either morphology of HPMC - stabilized amorphous KCZ particles 
Example 13 or Example 14 . This figure serves as supple - was not altered by the hot - melt extrusion process . This is 
mental analysis to DSC in its demonstration that the amor - evidenced by the absence of the broad endothermic event 
phous nature of the PVP - stabilized amorphous CBM par - 25 with the peak value at 142° C . observed with the physical 
ticles is not altered by hot - melt extrusion with a non - mixture , which peak is associated with the melting of 
solubilizing carrier system when extrusion temperatures are crystalline KCZ in the presence of the other excipients . This 
well below the T , the particle composite . figure therefore demonstrates that the morphology of the 
FIG . 16 comparative dissolution profiles obtained accord - HPMC - stabilized amorphous KCZ particles is not altered by 
ing to Example 12 for samples made according to Example 30 hot - melt extrusion with a non - solubilizing carrier formula 
13 and samples made according to Example 14 . The figure tion when extrusion temperature is sufficiently lower than 
demonstrates that the dissolution rate of CBM is faster in the the Te of the particle composite . 
case of the extrudates than the amorphous particles alone FI?S . 20a - 20b depict SEM images obtained according to 
with 93 % drug release in 10 minutes compared to 78 % , Example 2 of samples prepared according to Example 17 
respectively . This figure demonstrates that hot - melt extrud - 35 ( FIG . 20a ) and samples prepared according Example 18 
ing PVP - stabilized amorphous CBM particles in a hydro - ( FIG . 206 ) . FIG . 20a depicts a large aggregate of fine 
philic carrier improves the dissolution properties of the crystalline DNZ particles , with some of the smaller particles 
particles . This improvement is the result of increased surface having diameters near 100 nm . FIG . 20b depicts fine crys 
area and enhanced wettability of the drug particles by talline DNZ particles hot - melt extruded with a non - solubi 
deaggregation and dispersion of the particles into a hydro - 40 lizing polymeric carrier . It can be seen from the figure that 
philic carrier via the hot - melt extrusion process . large aggregates of fine crystalline DNZ particles are broken 
FIG . 17 depicts comparative dissolution profiles for up and dispersed within the polymeric matrix as discernable , 
samples made according to Example 13 and Example 14 in individualized particles by the hot - melt extrusion process . 
which the amount of CBM added to each dissolution vessel Additionally , it can be seen that the individual DNZ particles 
( 200 mg / 900 ml ) was several times greater than the equi - 45 are not solubilized by the polymeric carrier during hot - melt 
librium saturation solubility . This is in contrast to the extrusion . 
previous figure where the concentration of the drug in each In view of the present disclosure , the invention provides 
dissolution vessel ( 10 mg / 900 ml ) was below the equilib - a pharmaceutical composition possessing a stabilized 
rium solubility . This figure demonstrates that extrudates release profile , the composition comprising fine drug - con 
containing CBM amorphous particles reach higher levels of 50 taining particles dispersed in a nonsolubilizing and stabiliz 
supersaturation with a much more rapid dissolution rate than ing carrier , the pharmaceutical composition having been 
the amorphous particles alone . Because of the increased prepared by a method comprising the step of : providing a 
amount of material in each dissolution vessel , the hydro - charge of fine drug - containing particles of a therapeutic 
phobic attraction of the amorphous CBM particles in the compound ; 
dissolution media that causes them to aggregate and which 55 providing a charge of stabilizing and non - solubilizing hot 
impedes dissolution was more pronounced . This hydropho - melt extrudable carrier ; and 
bic attraction is greatly reduced by hot - melt extruding the mixing and hot - melting extruding the charges to form the 
CBM amorphous particles in a hydrophilic carrier which hot - melt extruded pharmaceutical composition ; wherein a 
renders the particles more wettable , and thus increases the substantial majority of the fine drug particles are not 
rate and extent of dissolution . 60 agglomerated or aggregated during the step of hot - melt 
FIG . 18 depicts comparative dissolution profiles for extruding . 
samples made according to Example 13 and samples made As used herein , the term " opaquant ” is intended to mean 
according to Example 14 before and after storage according a compound used to render a composition opaque . May be 
to Example 4 at conditions of 40° C . and 75 % relative used alone or in combination with a colorant . Such com 
humidity in aluminum induction sealed high density poly - 65 pounds include , by way of example and without limitation , 
ethylene bottles for a period of two weeks . It can be seen in titanium dioxide and other materials known to one of 
the figure that the dissolution profile of the hot - melt ordinary skill in the art . 
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Some of the materials listed herein may be too brittle or organoleptic effect desired . Flavors will be present in any 
may have Tg values that are generally too high rendering amount as desired by those of ordinary skill in the art . 
them too difficult to extrude . The glass transition tempera Particularly preferred flavors are the grape and cherry fla 
ture is reduced upon the addition of a plasticizer . As used vors and citrus flavors such as orange . 
herein , the glass transition temperature is taken to mean the 5 It should be understood , that compounds used in the art of 
temperature at which a solid material softens or melts ( or the pharmaceutical formulation generally serve a variety of 
glass transition temperature ( Tg ) is the temperature at which functions or purposes . Thus , if a compound named herein is 
a polymer changes during the heat cycle from a brittle mentioned only once or is used to define more than one term 
substance ( glass ) to a rubbery mass ) . Such materials can be herein , its purpose or function should not be construed as 
combined with one or more plasticizers to render them 10 being limited solely to that named purpose ( s ) or function ( s ) . 
thermoformable . Plasticizers , such as low molecular weight The solid substrate of the invention will include an active 
PEG , generally broaden the average molecular weight of a agent when included in a dosage form . Generally an effec 
polymer in which they are included thereby lowering its tive amount of active agent is included . By the term “ effec 
glass transition temperature or softening point . Plasticizers tive amount ” , it is understood that , with respect to , for 
also generally reduce the viscosity of a polymer . It is 15 example , pharmaceuticals , a therapeutically effective 
possible the plasticizer will impart some particularly advan - amount is contemplated . A therapeutically effective amount 
tageous physical properties to the film of the invention is the amount or quantity of drug that is sufficient to elicit the 
Plasticizers useful in the invention can include , by way of required or desired therapeutic response , or in other words , 
example and without limitation , low molecular weight poly - the amount that is sufficient to elicit an appreciable biologi 
mers , oligomers , copolymers , oils , small organic molecules , 20 cal response when administered to a patient . 
low molecular weight polyols having aliphatic hydroxyls , The active agent can be present in its free acid , free base 
ester - type plasticizers , glycol ethers , poly ( propylene glycol ) , or pharmaceutically acceptable salt form . As used herein , 
multi - block polymers , single block polymers , low molecular “ pharmaceutically acceptable salts ” refer to derivatives of 
weight poly ( ethylene glycol ) , citrate ester - type plasticizers , the disclosed compounds wherein the active agent is modi 
triacetin , propylene glycol and glycerin . Such plasticizers 25 fied by making acid or base salts thereof . Examples of 
can also include ethylene glycol , 1 , 2 - butylene glycol , 2 , 3 - pharmaceutically acceptable salts include , but are not lim 
butylene glycol , styrene glycol , diethylene glycol , triethyl - ited to , mineral or organic acid salts of the drug . The 
ene glycol , tetraethylene glycol and other poly ( ethylene pharmaceutically acceptable salts include the conventional 
glycol ) compounds , monopropylene glycol monoisopropyl non - toxic salts , for example , from non - toxic inorganic or 
ether , propylene glycol monoethyl ether , ethylene glycol 30 organic acids . For example , such conventional non - toxic 
monoethyl ether , diethylene glycol monoethyl ether , sorbitol salts include those derived from inorganic acids such as 
lactate , ethyl lactate , butyl lactate , ethyl glycolate , dibutylse - hydrochloric , hydrobromic , sulfuric , sulfonic , sulfamic , 
bacate , acetyltributylcitrate , triethyl citrate , acetyl triethyl phosphoric , nitric and the like ; and the salts prepared from 
citrate , tributyl citrate and allyl glycolate . All such plasti - organic acids such as amino acids , acetic , propionic , suc 
cizers are commercially available from sources such as 35 cinic , glycolic , stearic , lactic , malic , tartaric , citric , ascorbic , 
Aldrich or Sigma Chemical Co . It is also contemplated and pamoic , maleic , hydroxymaleic , phenylacetic , glutamic , 
within the scope of the invention , that a combination of benzoic , salicylic , sulfanilic , 2 - acetoxybenzoic , fumaric , 
plasticizers may be used in the present formulation . The toluenesulfonic , methanesulfonic , ethane disulfonic , oxalic , 
PEG based plasticizers are available commercially or can be isethionic , and other known to those of ordinary skill in the 
made by a variety of methods , such as disclosed in Poly 40 pharmaceutical sciences . Lists of suitable salts are found in 
( ethylene glycol ) Chemistry : Biotechnical and Biomedical texts such as Remington ' s Pharmaceutical Sciences , 18th 
Applications ( J . M . Harris , Ed . ; Plenum Press , NY ) the Ed . ( Alfonso R . Gennaro , ed . ; Mack Publishing Company , 
disclosure of which is hereby incorporated by reference . Easton , Pa . , 1990 ) ; Remington : the Science and Practice of 
Preservatives include compounds used to prevent the Pharmacy 19th Ed . ( Lippincott , Williams & Wilkins , 1995 ) ; 
growth of microorganisms . Suitable preservatives include , 45 Handbook of Pharmaceutical Excipients , 3rd Ed . ( Arthur H . 
by way of example and without limitation , benzalkonium Kibbe , ed . ; Amer . Pharmaceutical Assoc . , 1999 ) ; the Phar 
chloride , benzethonium chloride , benzyl alcohol , cetylpyri - maceutical Codex : Principles and Practice of Pharmaceu 
dinium chloride , chlorobutanol , phenol , phenylethyl alco tics 12th Ed . ( Walter Lund ed . ; Pharmaceutical Press , Lon 
hol , phenylmercuric nitrate and thimerosal and others don , 1994 ) ; The United States Pharmacopeia : The National 
known to those of ordinary skill in the art . 50 Formulary ( United States Pharmacopeial Convention ) ; and 
As used herein , the term " flavorant ” is intended to mean Goodman and Gilman ' s : the Pharmacological Basis of 
a compound used to impart a pleasant flavor and often odor Therapeutics ( Louis S . Goodman and Lee E . Limbird , eds . ; 
to a pharmaceutical preparation . Exemplary flavoring agents McGraw Hill , 1992 ) , the disclosures of which are hereby 
or flavorants include synthetic flavor oils and flavoring incorporated by reference . 
aromatics and / or natural oils , extracts from plants , leaves , 55 The phrase " pharmaceutically acceptable ” is employed 
flowers , fruits and so forth and combinations thereof . These herein to refer to those compounds , materials , compositions , 
may also include cinnamon oil , oil of wintergreen , pepper - and / or dosage forms which are , within the scope of sound 
mint oils , clove oil , bay oil , anise oil , eucalyptus , thyme oil , medical judgment , suitable for use in contact with the tissues 
cedar leave oil , oil of nutmeg , oil of sage , oil of bitter of human beings and animals without excessive toxicity , 
almonds and cassia oil . Other useful flavors include vanilla , 60 irritation , allergic response , or other problem or complica 
citrus oil , including lemon , orange , grape , lime and grape - tion , commensurate with a reasonable benefit / risk ratio . 
fruit , and fruit essences , including apple , pear , peach , straw - As used herein , the terms “ therapeutic compound ” , 
berry , raspberry , cherry , plum , pineapple , apricot and so " therapeutic agent " , " active agent " and " drug ” are used 
forth . Flavors that have been found to be particularly useful interchangeably , unless otherwise specified . The process of 
include commercially available orange , grape , cherry and 65 the invention can be used to prepare composition and dosage 
bubble gum flavors and mixtures thereof . The amount of forms comprising essentially any one or more active agents . 
flavoring may depend on a number of factors , including the Active agents include physiological substances or pharma 
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cological active substances that produce a systemic or interstitial cystitis agents , cellulose sodium phosphate , anti 
localized effect or effects on animals and human beings . impotence agents , acetohydroxamic acid ( aha ) , genitouri 
Active agents also include pesticides , herbicides , insecti - nary irrigants , cystine - depleting agents , urinary alkalinizers , 
cides , antioxidants , plant growth instigators , sterilization urinary acidifiers , anticholinergics , urinary cholinergics , 
agents , catalysts , chemical reagents , food products , nutri - 5 polymeric phosphate binders , vaginal preparations , and 
ents , cosmetics , vitamins , minerals , dietary supplements , diuretics . Exemplary respiratory agents include bronchodi 
sterility inhibitors , fertility instigators , microorganisms , fla - lators , leukotriene receptor antagonists , leukotriene forma 
voring agents , sweeteners , cleansing agents and other such tion inhibitors , nasal decongestants , respiratory enzymes , 
compounds for pharmaceutical , veterinary , horticultural , lung surfactants , antihistamines , nonnarcotic antitussives , 
household , food , culinary , agricultural , cosmetic , industrial , 10 and expectorants . Exemplary central nervous system agents 
cleansing , confectionery and flavoring applications . The include CNS stimulants , narcotic agonist analgesics , nar 
active agent can be present in its neutral , ionic , salt , basic , cotic agonist - antagonist analgesics , central analgesics , acet 
acidic , natural , synthetic , diastereomeric , isomeric , aminophen , salicylates , nonnarcotic analgesics , nonsteroidal 
enantiomerically pure , racemic , hydrate , chelate , derivative , anti - inflammatory agents , agents for migraine , antiemetic / 
analog , or other common form . 15 antivertigo agents , antianxiety agents , antidepressants , 
Further therapeutic compounds which can be formulated antipsychotic agents , cholinesterase inhibitors , nonbarbitu 
into the present composition also include antibacterial sub - rate sedatives and hypnotics , nonprescription sleep aids , 
stance , antihistamine ( histamine receptor inhibitor ) , decon - barbiturate sedatives and hypnotics , general anesthetics , 
gestant , anti - inflammatory agent , antiparasitic agent , antivi - anticonvulsants , muscle relaxants , antiparkinson agents , 
ral agent , local anesthetic , antifungal agent , amoebicidal 20 adenosine phosphate , cholinergic muscle stimulants , disul 
agent , trichomonocidal agent , analgesic agent , antiarthritic furam , smoking deterrents , riluzole , hyaluronic acid deriva 
agent , antiasthmatic agent , anticoagulant agent , anticonvul tives , and botulinum toxins . Exemplary gastrointestinal 
sant agent , antidepressant agent , antidiabetic agent , antine - agents including H pylori agents , histamine H2 antagonists , 
oplastic agent , antipsychotic agent , neuroleptic agent , anti proton pump inhibitors , sucralfate , prostaglandins , antacids , 
hypertensive agent , muscle relaxant , depressant agent , 25 gastrointestinal anticholinergics / antispasmodics , mesala 
hypnotic agent , sedative agent , psychic energizer , tranquil - mine , olsalazine sodium , balsalazide disodium , sulfasala 
izer , antiparkinson agent , muscle contractant , anti - microbial zine , celecoxib , infliximab , esomeprazole , famotidine , lan 
agent , antimalarial agent , hormonal agent , contraceptive soprazole , omeprazole , pantoprazole , rabeprazole , tegaserod 
agent , sympathomimetic agent , diuretic agent , hypoglyce - maleate , laxatives , antidiarrheals , antiflatulents , lipase 
mic agent , ophthalmic agent , anti - hypercholesterolemia 30 inhibitors , GI stimulants , digestive enzymes , gastric acidi 
agent , anti - hypocholesterolemia agent , electrolyte , diagnos - fiers , hydrocholeretics , gallstone solubilizing agents , mouth 
tic agent , cardiovascular drug , vitamin , nutrient , other type and throat products , systemic deodorizers , and anorectal 
of therapeutic compound known to those of ordinary skill in preparations . Exemplary anti - infective agents including 
the pharmaceutical sciences , and combinations thereof . penicillins , such as amoxicilin , cephalosporins and related 
Representative active agents include nutrients and nutri - 35 antibiotics , carbapenem , monobactams , chloramphenicol , 
tional agents , hematological agents , endocrine and meta - quinolones , fluoroquinolones , tetracyclines , macrolides , 
bolic agents , cardiovascular agents , renal and genitourinary such as azithromycin , clarithromycin , and the like , spectino 
agents , respiratory agents , central nervous system agents , mycin , streptogramins , vancomycin , oxalodinones , lincos 
gastrointestinal agents , anti - infective agents , biologic and amides , oral and parenteral aminoglycosides , colistimethate 
immunological agents , dermatological agents , ophthalmic 40 sodium , polymyxin B sulfate , bacitracin , metronidazole , 
agents , antineoplastic agents , and diagnostic agents . Exem - sulfonamides , nitrofurans , methenamines , folate antago 
plary nutrients and nutritional agents include as minerals , nists , antifungal agents , such as fluconazole , voriconazole , 
trace elements , amino acids , lipotropic agents , enzymes and and the like , antimalarial preparations , antituberculosis 
chelating agents . Exemplary hematological agents include agents , amebicides , antiviral agents , antiretroviral agents , 
hematopoietic agents , antiplatelet agents , anticoagulants , 45 leprostatics , antiprotozoals , anthelmintics , and CDC anti 
coumarin and indandione derivatives , coagulants , throm - infective agents . Exemplary biologic and immunological 
bolytic agents , antisickling agents , hemorrheologic agents , agents including immune globulins , monoclonal antibody 
antihemophilic agents , hemostatics , plasma expanders and agents , antivenins , agents for active immunization , aller 
hemin . Exemplary endocrine and metabolic agents include genic extracts , immunologic agents , and antirheumatic 
sex hormones , uterine - active agents , bisphosphonates , 50 agents . Exemplary antineoplastic agents include alkylating 
antidiabetic agents , glucose elevating agents , adrenocortical agents , antimetabolites , antimitotic agents , epipodophyllo 
steroids , parathyroid hormone , thyroid drugs , growth hor - toxins , antibiotics , hormones , enzymes , radiopharmaceuti 
mones , posterior pituitary hormones , octreotide acetate , cals , platinum coordination complex , anthracenedione , sub 
imiglucerase , calcitonin - salmon , sodium phenylbutyrate , stituted ureas , methylhydrazine derivatives , 
betaine anhydrous , cysteamine bitartrate , sodium benzoate 55 imidazotetrazine derivatives , cytoprotective agents , DNA 
and sodium phenylacetate , bromocriptine mesylate , caber - topoisomerase inhibitors , biological response modifiers , ret 
goline , agents for gout , and antidotes . inoids , rexinoids , monoclonal antibodies , protein - tyrosine 
Exemplary cardiovascular agents include nootropic kinase inhibitors , porfimer sodium , mitotane ( o , p - ddd ) , and 
agents , antiarrhythmic agents , calcium channel blocking arsenic trioxide . Exemplary diagnostic agents include in 
agents , vasodilators , antiadrenergics / sympatholytics , renin 60 vivo diagnostic aids , in vivo diagnostic biologicals , and 
angiotensin system antagonists , antihypertensive combina - radiopaque agents . 
tions , agents for pheochromocytoma , agents for hyperten - Representative antibacterial substances are beta - lactam 
sive emergencies , antihyperlipidemic agents , antihyperlipi - antibiotics , tetracyclines , chloramphenicol , neomycin , 
demic combination products , vasopressors used in shock , gramicidin , bacitracin , sulfonamides , aminoglycoside anti 
potassium removing resins , edetate disodium , cardioplegic 65 biotics , tobramycin , nitrofurazone , nalidixic acid , penicillin , 
solutions , agents for patent ductus arteriosus , and sclerosing tetracycline , oxytetracycline , chlorotetracycline , erythromy 
agents . Exemplary renal and genitourinary agents include cin , cephalosporins and analogs and the antimicrobial com 
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bination of fludalanine / pentizidone . Other representative antidiabetic agents , such as nateglinide , repaglinide , insulin , 
antibacterial agents include of the poorly water - soluble somatostatin and its analogs , chlorpropamide , isophane 
pyrridone - carboxylic acid type such as benofloxacin , nali - insulin , protamine zinc insulin suspension , globin zinc insu 
dixic acid , enoxacin , ofloxacin , amifloxacin , flumequine , lin , and extended insulin zinc suspension . 
tosfloxacin , piromidic acid , pipemidic acid , miloxacin , oxo - 5 Representative antineoplastics are chlorambucil , cyclo 
linic acid , cinoxacin , norfloxacin , ciprofloxacin , pefloxacin , phosphamide , triethylenemelamine , thiotepa , hexamethyl 
lomefloxacin , enrofloxacin , danofloxacin , binfloxacin , sara melamine , busulfan , carmustine , lomustine , dacarbazine , 
floxacin , ibafloxacin , difloxacin and salts thereof . arabinoside cytosine , mercaptopurine , azathiprine , vincris 
Representative antiparasitic compounds are ivermectin , tine , vinblastine , taxol , etoposide , actinomycin D , daunoru 
bephenium , hydroxynaphthoate , praziquantel , nifurtimox , 10 bicin , doxorubicin , bleomycin , mitomycin ; cisplatin ; 
benznidasol , dichlorophen and dapsone . Representative hydroxyurea , procarbazine , aminoglutethimide , tamoxifen , 
anti - malarial compounds are 4 - aminoquinolines , 8 - amino - adriamycin , fluorouracil , methotrexate , mechlorethamine , 
quinolines and pyrimethamine . uracil mustard , 5 - fluorouracil , 6 - 6 - thioguanine and procar 
Representative antiviral compounds are protease inhibi bazine asparaginase . 
tors , neuramidinase inhibitors , commercially available com - 15 Representative steroidal drugs are prednisone , predniso 
pounds , acyclovir and interferon . lone , cortisone , cortisol and triamcinolone ; androgenic ste 
Representative anti - inflammatory drugs include specific roids such as methyltesterone , and fluoxmesterone ; estro 
or selective COX - 2 receptor inhibitors , rofecoxib , celecoxib , genic steroids such as 17ß - estradiol , a - estradiol , estriol , 
etodolac , flurbiprofen , ibuprofen , ketoprofen , ketorolac , a - estradiol 3 benzoate , and 17 - ethynylestradiol - 3 - methyl 
nabumetone , piroxicam , suprofen , tolmetin , zileuton , ste - 20 ether ; progestational steriods such as progesterone , 19 - nor 
roids , cyclooxygenase inhibitors , cortisone , hydrocortisone , pregn - 4 - ene - 3 , 20 - dione , 17 - hydroxy - 19 - nor - 17 - a - pregn - 5 
betamethasone , dexamethasone , fluocortolone , predniso - ( 10 ) - ene - 20 - yn - 3 - one , 17a - ethynyl - 17 - hydroxy - 5 ( 10 ) - es 
lone , phenylbutazone , triamcinolone , sulindac , indometha - tren - 3 - one , and 9B , 10a - pregna - 4 , 6 - diene - 3 , 20 - dione . 
cin , salicylamide , naproxen , colchicine , fenoprofen , Representative estrogen antagonist - agonist drugs are clo 
diclofenac , indoprofen , dexamethasone , allopurinol , oxy - 25 miphene citrate and raloxifene HC1 .
phenbutazone , probenecid and sodium salicylamide . Representative antipsychotics are prochlorperazine , 
Representative analgesic drugs are diflunisal , aspirin , lithium carbonate , lithium citrate , thioridazine , molindone , 
ibuprofen , profen - type compounds , morphine , codeine , lev - fluphenazine , trifluoperazine , perphenazine , amitriptyline , 
orphanol , hydromorphone , oxymorphone , oxycodone , trifluopromazine , chlorpromazine , clozapine , haloperidol , 
hydrocodone , naloxene , levallorphan , etorphine , fentanyl , 30 loxapine , mesoridazine , olanzapine , quetiapine , ziprasidone , 
bremazocine , meperidine , nalorphine , tramadol , and acet - risperidone , pimozide , mesoridazine besylate , chlorprothix 
aminophen . ene , and thiothixene . 
Representative antihistamines and decongestants are Representative hypnotics and sedatives are pentobarbital 
acrivastine , astemizole , norastemizol , brompheniramine , sodium , phenobarbital , secobarbital , thiopental , heterocyclic 
cetirizine , clemastine , diphenhydramine , ebastine , famoti - 35 hypnotics , dioxopiperidines , imidazopyridines , such as 
dine , fexofenadine , meclizine , nizatidine , perilamine , pro - zolpidem tartrate , glutarimides , diethylisovaleramide , 
methazine , ranitidine , terfenadine , chlorpheniramine , cime - a - bromoisovaleryl urea , urethanes , disulfanes . 
tidine , tetrahydrozoline , tripolidine , loratadine , Representative antihypertensives are nifedipine , vera 
desloratadine , antazoline , and pseudoephedrine . pamil , diltiazem , felodipine , amlodipine , isradipine , nicar 
Representative antiasthma drugs are theophylline , ephed - 40 dipine , nisoldipine , nimodipine , bepridil , enalapril , capto 
rine , beclomethasone dipropionate and epinephrine . pril , lisinopril , benazepril , enalaprilat , espirapril , fosinopril , 
Representative anticoagulants are heparin , bishydroxy - moexipril , quinapril , ramipril , perindopril , trandolapril , 
coumarin , and warfarin . furosemide , bumetanide , ethacrynic acid , torsemide , 
Representative psychic energizers are isocoboxazid , nia muzolimide , azosemide , piretanide , tripamide , hydrochloro 
lamide , phenelzine , imipramine , tranycypromine , and parg - 45 thiazide , chlorthalidone , indapamide , metozalone , cyclopen 
lyene . thiazide , xipamide , mefruside , dorzolamide , acetazolamide , 
Representative anticonvulsants are clonazepam , pheno methazolamide , ethoxzolamide , cyclothiazide , clopamide , 
barbital , mephobarbital , primidone , enitabas , diphenylhy dichlorphenamide , hydroflumethiazide , trichlormethiazide , 
dantion , ethltion , pheneturide , ethosuximide , diazepam , polythiazide , benzothiazide , spironolactone , methyldopa , 
phenytoin carbamazepine , lamotrigine , lorazepam , leveti - 50 hydralazine , clonidine , chlorothiazide , deserpidine , timolol , 
racetam , oxcarbazepine , topiramate , valproic acid , chlora - propranolol , metoprolol , pindolol , acebutolol , prazosin 
zepate , gabapentin , felbamate , tiagabine and zonisamide . hydrochloride , methyl dopa ( L - B - 3 , 4 - dihydroxyphenylala 
Representative antidepressants are amitriptyline , chlordi - nine ) , pivaloyloxyethyl ester of a - methyldopa hydrochlo 
azepoxide perphenazine , protriptyline , imipramine , dox ride dihydrate , candesartan cilexetil , eprosartan mesylate , 
epin , venlafaxine , O - desmethyl venlafaxine , citalopram , 55 losartan potassium , olmersartan medoxomil , telmisartan , 
escitalopram , bupropion , clomipramine , desipramine , nefa - valsartan , and reserpine . 
zodone , fluoxetine , fluvoxamine , maprotiline , mirtazapine , Representative tranquilizers are chloropromazine , pro 
nortriptyline , paroxetine , phenelzine , tranylcypromine , ser - mazine , fluphenazine , reserpine , deserpidine , meprobamate , 
traline , trazodone , trimipramine , and amoxapine . and benezodiazepines ( anxyiolitic , sedatives , and hypnotics ) 
Representative antidiabetics are sulphonylureas , such as 60 such as alprazolam , chlordiazepoxide , diazepam , lorazepam , 
tolbutamide , chlorpropamide , tolazamide , acetohexamide , oxazepam , temazepam , and triazolam . 
glibenclamide , gliclazide , 1 - butyl - 3 - metanilylurea , carbuta - Representative anti - spasmodics and muscle contractants 
mide , glibonuride , glipizide , glyburide , gliquidone , glisox are atropine , scopolamine , methscopolamine , oxyphe 
epid , glybuthiazole , glibuzole , glyhexamide , glymidine , nonium , papaverine , and prostaglandins such as PGE1 
glypinamide , phenbutamide , and tolcyclamide ; thiazolidin - 65 PGE2 PGF1 , PGFza and PGA . 
ediones ( glitazones ) , such as rosiglitazone , pioglitazone , and Representative local anesthetics are benzocaine , procaine , 
troglitazone ; biguanidines , such as metformin ; and other lidocaine , maepaine , piperocaine , tetracaine and dibucaine . 
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Representative muscle relaxants are alcuronium , alos in Argentina ( Administración Nacional de Medicamentos , 
etron , aminophylline , baclofen , carisoprodol , chlorphenesin , Alimentos y Tecnología Medica ( ANMAT ) and Brazil 
chlorphenesin carbamate , chlorzoxazone , chlormezanone , ( Ministério da Saúde ) ) , Australia ( Department of Health and 
dantrolene , decamethonium , dyphylline , eperisione , ethav Ageing ) , Africa ( in particular in South Africa ( Department 
erine , gallamine triethiodide , hexafluorenium , metaxalone , 5 of Health ) and Zimbawe ( Ministry of Health and Child 
metocurine iodide , orphenadrine , pancuronium , papaverine , Welfare ) , ) or Asia ( in particular Japan ( Ministry of Health , pipecuronium , theophylline , tizanidine , tolperisone , tubocu Labour and Welfare ) , Taiwan ( Executive Yuans Department 
rarine , vecuronium , idrocilamide , ligustilide , cnidilide , sen of Health ) , and China ( Ministry of Health People ' s Republic kyunolide , succinylcholine - chloride , danbrolene , cycloben of China ) ) as being suitable for administration to humans or zaprine , methocarbamol , diazepam , mephenesin , 10 animals . Preferred embodiments of the invention include methocarbomal , trihexylphenidyl , pridinol ( pridinolum ) , those wherein the active substance is pharmacologically or and biperiden . 
biologically active or wherein the environment of use is the Representative anti - Parkinson agents are carbidopa , 
levodopa , ropinirole , pergolide mesylate , rasagiline , GI tract of a mammal . 
pramipexole , entacapone , benzacide , bromocriptine , selegi - 15 The amount of therapeutic compound incorporated in 
line , amantadine , trihexylphenidyl , biperiden , pridinol each dosage form will be at least one or more unit doses and 
mesylate , and tolcapone . can be selected according to known principles of pharmacy . 
Representative anti - Dementia and anti - Alzheimer disease An effective amount of therapeutic compound is specifically 
agents are memantine , donepexil , galantamine , rivastig contemplated . By the term “ effective amount ” , it is under 
mine , and tacrine 20 stood that , with respect to , for example , pharmaceuticals , a Representative sympathomimetic drugs are albuterol , epi pharmaceutically effective amount is contemplated . A phar 
nephrine , amphetamine ephedrine and norepinephrine . maceutically effective amount is the amount or quantity of Representative cardiovascular drugs are procainamide , a drug or pharmaceutically active substance which is suffi procainamide hydrochloride , amyl nitrite , nitroglycerin , cient to elicit the required or desired therapeutic response , or 
dipyredamole , sodium nitrate and mannitol nitrate . 23 in other words , the amount which is sufficient to elicit an 25 in Representative diuretics are chlorothiazide , acetazol appreciable biological response when administered to a amide , methazolamide , triamterene , furosemide , indap 
amide , and flumethiazide . patient . The appreciable biological response may occur as a 
Representative n - blockers are caravedilol , pindolol , pro result of administration of single or multiple unit doses of an 
pranolol , practolol , metoprolol , esmolol , oxprenolol , 30 active substance . A dosage form according to the invention 
timolol , atenolol , alprenolol , and acebutolol . that comprises two or more active agents can include 
Representative phosphodiesterase inhibitors are vardena subtherapeutic amounts of one or more of those active 
fil HCl and sildenafil citrate . agents such that an improved , additive or synergistic clinical 
Representative antilipemic agents are atorvastatin , ceriv benefit is provided by the dosage form . By “ subtherapeutic 
astatin , clofibrate , fluvastatin , gemfibrozil , lovastatin , mevi - 35 amount is meant an amount less than that typically recog 
nolinic acid , niacin , pravastatin , and simvastatin . nized as being therapeutic on its own in a subject to which 
Representative antigout drugs are colchicine , allopurinol , the dosage form is administered . Therefore , a dosage form 
probenecid , sulfinpyrazone , and benzbromadone . can comprise a subtherapeutic amount of a first drug and a 
Representative nutritional agents are ascorbic acid , nia - therapeutic amount of a second drug . Alternatively , a dosage 
cin , nicotinamide , folic acid , choline biotin , panthothenic 40 form can comprise a subtherapeutic amount of a first drug 
acid , and vitamin B12 , essential amino acids ; essential fats . and a subtherapeutic amount of a second drug . 
Representative electrolytes are calcium gluconate , cal The term “ unit dose ” is used herein to mean a dosage form cium lactate , potassium chloride , potassium sulfate , sodium 
chloride , potassium fluoride , ferrous lactate , ferrous glucon containing a quantity of the therapeutic compound , said 
ate . ferrous sulfate , ferrous fumurate and sodium lactate . 45 quantity being such that one or more predetermined units 
Representative drugs that act on a - adrenergic receptors may be provided as a single therapeutic administration . 
are clonidine hydrochloride , prazosin , tamsulosin , terazosin , In view of the above description and the examples below , 
and doxazosin . one of ordinary skill in the art will be able to practice the 
Representative mild CNS stimulants are caffeine , invention as claimed without undue experimentation . The 
modafinil , and methylphenidate hydrochloride . foregoing will be better understood with reference to the 
The formulation of the invention can also be used with following examples that detail certain procedures for the 
unclassified therapeutic agents such as clopidrogel , which is preparation of formulations according to the present inven 
indicated for the reduction of atherosclerotic events ( myo tion . All references made to these examples are for the 
cardial infarction , stroke , and vascular death ) in patients purposes of illustration . The following examples should not 
with atherosclerosis documented by recent stroke , recent 55 be considered exhaustive , but merely illustrative of only a 
myocardial infarction , or established peripheral arterial dis - few of the many embodiments contemplated by the present 
ease . invention . 
The active agents ( drugs ) listed herein should not be 
considered exhaustive and is merely exemplary of the many 
embodiments considered within the scope of the invention . 60 Example 1 
Many other active agents can be administered with the 
formulation of the present invention . Suitable drugs are The following process was used to prepare a hot - melt 
selected from the list of drugs included herein as well as extruded composition according to the invention . The fol 
from any other drugs accepted by the U . S . F . D . A . or other l owing ingredients in the amounts indicated were used in 
similarly recognized authority in Canada ( Health Canada ) , 65 preparing hot - melt extruded control and sample composi 
Mexico ( Mexico Department of Health ) , Europe ( European tions containing itraconazole ( ITZ ) as the active agent . The 
Medicines Agency ( EMEA ) ) , South America ( in particular amounts are indicates in parts by weight . 
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air environment and then sealed without purging the con 
Poloxamer tainers prior to sealing . The containers were then stored as 
407 desired under a variety of conditions : 
Condition A : 25° C . and 60 % RH 
5 Condition B : 40° C . and 0 % RH 












OOOO vaaAWNE ORO ROA Saacacaca 100 -00 0 0 OOOOHOOOO 000000 - FOOOOOOOO Example 5 1 . 10 Formulation : 10 1 8 Micronized Cyclosporine ( mean particle diameter 2 
microns ) : 15 % 
Ethylcellulose : 40 % 
A Randcastle Microtruder RCP - 0750 hot - melt extruder Polyox 200M : 15 % 
equipped with a 6 mm round die was operated at 15 RPM , 15 LHPC : 8 % 
0 . 2 - 0 . 3 Drive Amps with an Extrusion Temperature of 100° Lactose 16 % 
C . to prepare the composition . All powders were blended in Xylitol : 5 % 
a v - shell blender prior to extrusion . Temperature zones were Vitamin E : 1 % 
set as follows : zone 1 : 90° C . , zone 2 : 95° C . , zone 3 : 100° A Randcastle Microtruder RCP - 0750 hot - melt extruder 
C . , die temperature 100° C . The powder blend was placed in 20 equipped with a 6 mm round die was operated at 15 RPM , 
a hopper that is located at the head of a vertical screw such 0 . 2 - 0 . 3 Drive Amps with an Extrusion Temperature of 100° 
that the material is flood fed by gravity . The residence time C . to prepare the composition . All powders were blended in 
of the material in the extruder was approximately three a V - shell blender prior to extrusion . Temperature zones were 
minutes . The extrudate was sheared into approximately one set as follows : zone 1 : 90° C . , zone 2 : 95° C . , zone 3 : 100° 
foot sections after exiting the die and placed on an aluminum 25 C . , die temperature 100° C . The powder blend was placed in 
sheets and allowed to cool at ambient conditions . a hopper that is located at the head of a vertical screw such 
Following preparation , the compositions can be analyzed that the material is flood fed by gravity . The residence time 
by scanning electron microscopy ( SEM ) , differential scan of the material in the extruder was approximately three 
ning calorimetry ( DSC ) , visual inspection , dissolution minutes . The extrudate was sheared into approximately one 
assays and other suitable methods of analysis . 30 foot sections after exiting the die and placed on an aluminum 
sheets and allowed to cool at ambient conditions . 
Example 2 
Example 6 
The fine drug - containing particles and compositions con 
taining them were analyzed by scanning electron micros - 35 The following procedure is used for the preparation of 
copy using a Hitachi S - 4500 scanning electron microscope . danazol nanoparticles using " spray freezing into liquid ” 
Samples were coated with Au / Pd and an accelerating voltage technology . 
of 5 kV was used . Danazol ( 0 . 2 % w / v ) and PVP K15 ( 0 . 2 % w / v ) were dis 
solved in acetonitrile ( 500 ml ) . Aliquots of the solution ( 75 
Example 3 40 ml ) were loaded into a high - pressure solution cell and 
atomized beneath the liquid nitrogen surface at 50 ml / min 
Changes in the degree of crystallization of the fine drug - constant flow using a model 100DX ISCO syringe pump 
containing particles , either neat or dispersed within a hot - ( ISCO , Inc . , Lincoln , Nebr . ) through a 127 um I . D . 
melt extruded composition , were determined and quantified polyetherether ketone ( PEEK ) tubing nozzle . The PEEK 
by differential scanning calorimetry . A TA Instruments 45 tubing acted as an insulating nozzle that prevented freezing 
Model 2920 calorimeter was used to conduct the analyses within the nozzle orifice . The resultant frozen microparticles 
The calorimeter was operated using the following param were collected and dried by a VirTis Advantage Tray 
eters : Lyophilizer ( VirTis Inc . , Gardiner , N . Y . ) . The resulting 
Nitrogen Purge Flow Rate : 150 ml /min product is a fine powder of aggregated nanoparticles of 
Sample Pan : Aluminum ( Closed ) 50 amorphous danazol complexed with PVP - K15 in a one to 
Sample Weight : 10 - 15 mg one ratio . 
Heating Rate : 10° C . / min 
Range : 20 - 200° C . Example 7 
The thermograms obtained from the DSC were analyzed 
using the TA Universal Analysis Software in which peak 55 The following procedure is used for the preparation of 
minimums are determined by linear baseline method with danazol nanoparticles using " evaporative precipitation into 
manually selected limits . aqueous solution ” ( EPAS ) technology . 
Danazol ( 2 % w / v ) and PVP K - 15 ( 1 % w / v ) were dis 
Example 4 solved in 200 ml of dichloromethane . This solution was 
60 pumped via an HPLC pump at 2 ml /min through a heat 
The hot - melt extruded compositions were exposed to a exchange coil set at 80° C . After heating , the solution was 
variety of different storage conditions prior to determining sprayed through a fine elliptical conical nozzle at 5000 psi 
their release profiles . Samples were stored in sealed con - constant pressure into a heated water bath ( 80° C . ) contain 
tainers . Depending upon the conditions being evaluated , the ing PVP K - 15 ( 1 % w / v ) dissolved in 200 ml deionized 
closed containers might include a desiccant such as a silica 65 water . The resultant dispersion was quenched frozen by 
gel mini - pack ( Poly Lam Production Corp . ) . The containers injecting it into liquid nitrogen and lyophilized as in 
were filled with hot - melt extruded compositions in an open example 6 . The resulting product is a fine powder of 
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aggregated nanoparticles of amorphous danazol complexed thereby its amorphous state if extruded at temperatures of 
with PVP - K15 in a two to one ratio . approximately 100° C . or below . The following is an 
example of a hot - melt extrusion formulation and process by 
Example 8 which a homogenous extrudate of individualized and stabi 
5 lized itraconazole / PVP - K25 amorphous microparticles can 
Hot - Melt Extrusion of Amorphous Fine Drug Particles of be produced 
Danazol Formulation : Because the fine drug particles described in examples 6 
and 7 contain PVP - K15 as a major constituent , which has a 
glass transition temperature of 150° C . , the nanoparticle 10 Component Quantity complex will maintain its integrity and thereby its amor 
phous state if extruded at temperatures of 100° C . or below . Itraconazole / PVP - K25 amorphous 50 % 
The following is an example of a hot melt extrusion formu microparticles ( Example 9 ) 
Poloxamer 407 35 % lation and process by which a homogenous extrudate of Sentry Poloyox WSR N80 ( PEO ) 15 % 
individualized and stabilized danazol / PVP K - 15 nanopar - 15 - 
ticles can be produced . 
Formulation : Process : 
Danazol nanoparticles according to examples 6 or 7 : 35 % A Randcastle Microtruder RCP - 0750 hot - melt extruder 
PEO 200M : 50 % equipped with a 4 mm round die was operated at 20 RPM , 
HPMC E15 : 15 % 20 0 . 1 - 0 . 2 drive amps , and at a melt temperature of 60° C . to 
Process : prepare the composition . All powders were blended in a 
A Randcastle Microtruder RCP - 0750 hot - melt extruder V - shell blender prior to extrusion . Temperature zones were 
equipped with a 6 mm round die was operated at 15 RPM , set as follows : zone 1 : 40° C . , zone 2 : 60° C . , zone 3 : 60° 
0 . 2 - 0 . 3 Drive Amps with an Extrusion Temperature of 90° C . , die temperature 60° C . The powder blend was placed in 
C . to prepare the composition . All powders were blended in 25 d in 25 a hopper that is located at the head of a vertical screw such 
a v - shell blender prior to extrusion . Temperature zones were that the material is flood fed by gravity . The residence time set as follows : zone 1 : 80° C . , zone 2 : 85° C . , zone 3 : 90° of the material in the extruder was approximately two C . , die temperature 90° C . The powder blend was placed in minutes . The extrudate was sheared into approximately one 
a hopper that is located at the head of a vertical screw such foot sections after exiting the die and placed on aluminum 
that the material is flood fed by gravity . The residence time 30 sheets and allowed to cool at ambient conditions . After 
of the material in the extruder was approximately three cooling , the extrudates were milled with a ceramic mortar 
minutes . The extrudate was sheared into approximately and pestle and passed through a 250 um sieve . 
one - foot sections after exiting the die and placed on an 
aluminum sheets and allowed to cool at ambient conditions . Example 11 
Example 9 
Changes in the degree of crystallization of the fine drug 
The following procedure is used for the preparation of containing particles , either neat or dispersed within a hot 
PVP - stabilized amorphous itraconazole particles using an melt extruded composition , were determined by X - ray dif 
evaporative co - precipitation technology . 40 fraction . A model 1710 X - ray diffractometer ( Philips 
Formulation : Electronic Instruments , Inc . , Mahwah , N . J . ) using a Cu2a 
monochromated x - ray source was used to conduct the analy 
ses with a 0 . 05° / 20 step size and a 2 second dwell time . The 
Component Quantity output data was plotted as peak intensity versus 20 angle , 
Itraconazole ( ITZ ) 50 % 45 and the plots were qualitatively analyzed for the presence of 
Polyvinylpyrrolidone 50 % peaks indicating crystallinity of the drug substance . 
( PVP ; grade K25 ) 
Dichloromethane 5 mL / g solids 
Example 12 
Solid components listed the table above were dissolved 50 
into the organic solvent with the use of an Aquasonic Model The dissolution profiles of the fine - drug containing par 
150T ultrasonicator . The solvent was then completely ticles , either neat or dispersed within a hot - melt extruded 
evaporated in a vacuum chamber at a temperature of 40° C . composition , were determined using a USP 27 Type II 
and pressure of 500 m Torr to yield a dry solid product . The paddle apparatus model VK7000 ( Varian Inc . , Palo Alto , 
solid product was subsequently triturated in a glass mortar 55 Calif . ) at 37° C . and 50 rpm paddle speed . 
and pestle for 2 to 5 minutes to yield PVP - stabilized The dissolution media was 900 ml of 0 . 1 N HC1 , and was 
amorphous itraconazole particles with individual particle de - aerated with helium for approximately 15 minutes before 
diameters ranging from 2 to 100 um . each dissolution test . In all cases where not otherwise 
specified , the equivalent to 10 mg of the active ingredient 
Example 10 60 was added to each dissolution vessel . 
Hot - Melt Extrusion of Amorphous Fine Drug Particles of 
Itraconazole Example 13 
Because the fine drug particles described in Example 9 
contain PVP - K25 as a major constituent , which has a glass 65 The following procedure is used for the preparation of 
transition temperature of approximately 150° C . , the amor - PVP - stabilized amorphous carbamazepine particles using an 
phous microparticle complex will maintain its integrity and evaporative co - precipitation technology . 
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Formulation : Formulation : 
Component Quantity Component Quantity 
Carbamazepine ( CBM ) 50 % Ketoconazole ( KCZ ) 50 % 
Polyvinylpyrrolidone 50 % Methocel E5 ( HPMC ) 50 % 
( PVP ; grade K30 ) Dichloromethane 2 mL / g solids 
Dichloromethane 5 mL / g solids 
Procedure : 
Procedure : 10 Ketoconazole was dissolved into the organic solvent with 
Solid components listed the table above were dissolved the use of an Aquasonic Model 150T ultrasonicator . The 
into the organic solvent with the use of an Aquasonic Model ketoconazole solution was then added into a glass mortar 
150T ultrasonicator . The solvent was then completely which contained the required amount of HPMC . Under a 
evaporated in a vacuum chamber at a temperature of 40° C . fume hood , the solution was well mixed with the HPMC 
and pressure of 500 m Torr to yield a dry solid product . The he 15 powder using a glass pestle until a colorless viscous gel was obtained . Most of the solvent was evaporated during this solid product was subsequently triturated in a glass mortar mixing process . The residual solvent was then completely 
and pestle for 2 to 5 minutes to yield PVP - stabilized evaporated in a vacuum chamber at temperature of 40° C . 
amorphous carbamazepine particles with individual particle and pressure of 500 m Torr to yield a dry solid product . The 
diameters ranging from 2 to 100 um . 20 solid product was subsequently milled in a ceramic media 
mill containing 20 to 30 ceramic milling balls one centime 
Example 14 ter in diameter for approximately one hour at a mill RPM 
value of 40 to 50 . The resulting product was HPMC 
Hot - Melt Extrusion of Amorphous Fine Drug Particles of stabilized amorphous ketoconazole particles with individual 
Carbamazepine os particle diameters ranging from 2 to 50 um . 
Because the fine drug particles described in Example 13 Example 16 contain PVP - K30 as a major constituent , which has a glass 
transition temperature of approximately 150° C . , the amor Hot - Melt Extrusion of Amorphous Fine Drug Particles of phous microparticle complex will maintain its integrity and Ketoconazole 
thereby its amorphous state if extruded at temperatures of 30 Because the fine drug particles described in Example 15 
approximately 100° C . or below . The following is an contain HPMC as a major constituent , which has a glass 
example of a hot - melt extrusion formulation and process by transition temperature in the range of 170 to 180° C . , the 
which a homogenous extrudate of individualized and stabi amorphous microparticle complex will maintain its integrity 
lized carbamazepine / PVP - K30 amorphous microparticles and thereby its amorphous state if extruded at temperatures 
can be produced . 35 of approximately 100° C . or below . The following is an 
Formulation : example of a hot - melt extrusion formulation and process by which a homogenous extrudate of individualized and stabi 
lized ketoconazole / HPMC amorphous microparticles can be 
produced . 
Component Quantity - 40 Formulation : 
Carbamazepine / PVP - K30 amorphous 50 % 
microparticles ( Example 13 ) 
Poloxamer 407 35 % Component Quantity QuantiSentry Poloyox WSR N80 ( PEO ) 15 % 
Ketoconazole / HPMC E3 amorphous 50 % 
45 microparticles ( Example 15 ) 
Process : Poloxamer 407 35 % 
A Randcastle Microtruder RCP - 0750 hot - melt extruder Sentry Poloyox WSR N80 ( PEO ) 15 % 
equipped with a 4 mm round die was operated at 20 RPM , 
0 . 1 - 0 . 2 Drive Amps at a melt temperature of 60° C . to Process : 
prepare the composition . All powders were blended in a 50 A Randcastle Microtruder RCP - 0750 hot - melt extruder 
V - shell blender prior to extrusion . Temperature zones were equipped with a 4 mm round die was operated at 20 RPM , 
set as follows : zone 1 : 40° C . , zone 2 : 60° C . , zone 3 : 60° 0 . 1 - 0 . 2 Drive Amps at a melt temperature of 60° C . to 
C . , die temperature 60° C . The powder blend was placed in prepare the composition . All powders were blended in a 
V - shell blender prior to extrusion . Temperature zones were a hopper that is located at the head of a vertical screw such set as follows : zone 1 : 40° C . , zone 2 : 60° C . , zone 3 : 60° that the material is flood fed by gravity . The residence time 55 C . , die temperature 60° C . The powder blend was placed in 
of the material in the extruder was approximately two a hopper that is located at the head of a vertical screw such minutes . The extrudate was sheared into approximately one that the material is flood fed by gravity . The residence time foot sections after exiting the die and placed on aluminum of the material in the extruder was approximately two 
sheets and allowed to cool at ambient conditions . After minutes . The extrudate was sheared into approximately one 
cooling , the extrudates were milled with a ceramic mortar 60 foot sections after exiting the die and placed on aluminum 
and pestle and passed through a 250 um sieve . sheets and allowed to cool at ambient conditions . 
Example 15 Example 17 
The following procedure is used for the preparation of 65 
HPMC - stabilized amorphous ketoconazole particles using a 
solvent evaporation technology . 
The following procedure is used for the preparation of 
crystalline Danazol nanoparticles by a wet milling technol 
ogy . 
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Formulation : 2 . Zhang , F . and J . W . McGinity , Properties of Hot - Melt 
Extruded Theophylline Tablets Containing Poly ( Vinyl 
Acetate ) . Drug Development and Industrial Pharmacy , 
Component Quantity 2000 . 26 ( 9 ) : p . 931 - 942 . 
Danazol ( DNZ ) 75 % 3 . Robinson , J . R . , J . W . McGinity , and P . Delmas , Effer 
Polyvinylpyrrolidone 25 % vescent granules and methods for their preparation . June 
( PVP ; grade K30 ) 2000 and November 2003 , Ethypharm : U . S . Pat . Nos . Deionized water 10 mL / g solids 6 , 071 , 539 and 6 , 649 , 186 . 
4 . Kothrade , S . , et al . , Method for producing solid dosing Procedure : 10 forms . 2003 : U . S . Pat . No . 6 , 528 , 089 W09927916 All components listed in the table above were added to a DE19753298 EP1035841 . size 000 grinding mill jar ( U . S . Stoneware , East Palestine , 
Ohio ) along with 15 , 2 cm diameter cylindrical Zirconia 5 . Aitken - Nichol , C . , F . Zhang , and J . W . McGinity , Hot Melt 
grinding media . The grinding jar was capped and allowed to Extrusion of Acrylic Films . Pharmaceutical Research , 
turn on rollers at a rate of 50 RPM for 10 days . The resulting 15 1996 . 13 ( 5 ) : p . 804 - 808 . 
suspension of danazol nanoparticles in water was then 6 . Grabowski , S . , et al . , Solid active extrusion compound 
rapidly frozen by pouring into liquid nitrogen . The frozen preparations containing low - substituted hydroxypropyl 
particles were then lyophilized in a VirTis Advantage bench - cellulose . 1999 : U . S . Pat . No . 5 , 939 , 099 WO9625151 
top freeze dryer . The resulting product was PVP - stabilized DE19504832 EP0809488 . 
nanocrystals of Danazol with individual particle diameters 20 7 . Repka , M . A . and J . W . McGinity , Hot - melt extruded films 
ranging from 1 um to 50 nm . for transmucosal & transdermal dung delivery applica 
Example 18 tions . Drug Delivery Technology , 2004 . 4 ( 7 ) : p . 40 , 42 , 44 - 47 . 
Hot - Melt Extrusion of Crystalline Danazol Nanoparticles 8 . Repka , M . A . , S . L . Repka , and J . W . McGinity . Bioad 
Because of the size of and the processing method use to 25 Because of the size of and the processing method use to 25 hesive hot - melt extruded film for topical and mucosal 
prepare the crystalline danazol nanoparticles , the particles adhesion applications and drug delivery and process for 
produced are highly aggregated . Therefore , the full benefit preparation thereof . Apr . 23 , 2002 : U . S . Pat . No . 6 , 375 , 
of particle size reduction is not achieved by nanocrystal 963 . 
production alone . By melt extruding danazol nanocrystals 9 . Breitenbach , J . and H . D . Zettler , Method for producing 
with a carrier formulation and extrusion parameters that do 30 solid sphereical materials containing a biologically active 
not solubilize danazol , the stable crystalline form of the drug substance . 2000 : WO 0024382 . 
is not altered and nanoparticle aggregates are broken up and 10 . de Brabander , C . , C . Vervaet , and J . P . Remon , Devel 
dispersed as individual nanoparticles within the hydrophilic , opment and evaluation of sustained release mini - matrices 
stabilizing extrudate carrier . The following is an example of prepared via hot melt extrusion . Journal of Controlled 
a hot - melt extrusion formulation and process by which a 35 Release , 2003 . 89 ( 2 ) : p . 235 - 247 . 
homogenous extrudate of individualized and stabilized 11 . de Brabander , C . , et al . , Bioavailability of ibuprofen from 
danazol nanocrystals can be produced . hot - melt extruded mini - matrices . International Journal of Formulation : Pharmaceutics , 2004 . 271 ( 1 - 2 ) : p . 77 - 84 . 
12 . Rosenberg , J . and J . Breitenbach , The production of 
40 active substance compositions in the form of a solid Component Quantity solution of the active substance in a polymer matrix , and 
Danazol nanocrystals 50 % active substance compositions produced by this process . 
( Example 17 ) 1998 : U . S . Pat . No . 5 , 741 , 519 WO 9629061 EP 0760654 Poloxamer 407 35 % DE 19509807 . Sentry Poloyox WSR 15 % 
N80 ( PEO ) 45 13 . Six , K . , et al . , Characterization of Solid Dispersions of Itraconazole and Hydroxypropylmethylcellulose Pre 
pared by Melt Extrusion , Part II . Pharmaceutical Process : Research , 2003 . 20 ( 7 ) : p . 1047 - 1054 . A Randcastle Microtruder RCP - 0750 hot - melt extruder 14 . Six , K . , et al . , Thermal Properties of Hot - Stage Extru equipped with a 4 mm round die was operated at 20 RPM , 
0 . 1 - 0 . 2 Drive Amps at a melt temperature of 60° C . to 50 dates of Itraconazole and Eudragit E100Phase Separa 
prepare the composition . All powders were blended in a tion and Polymorphism . Journal of Thermal Analysis and 
V - shell blender prior to extrusion . Temperature zones were calorimetry , 2002 . 68 : p . 591 - 601 . 
set as follows : zone 1 : 40° C . , zone 2 : 60° C . , zone 3 : 60° 15 . Six , K . , et al . , Identification of Phase Separation in Solid 
C . , die temperature 60° C . The powder blend was placed in Dispersions of Itraconazole and Eudragit E100 Using 
a hopper that is located at the head of a vertical screw such 55 Microthermal Analysis . Pharmaceutical Research , 2003 . 
that the material is flood fed by gravity . The residence time 20 ( 1 ) : p . 135 - 138 . 
of the material in the extruder was approximately two 16 . Six , K . , et al . , Increased Physical Stability and Improved 
minutes . The extrudate was sheared into approximately one Dissolution Properties of Itraconazole , a Class II Drug , 
foot sections after exiting the die and placed on aluminum by Solid Dispersions that Combine Fast - and Slow - Dis 
sheets and allowed to cool at ambient conditions . 60 solving Polymers . Journal of Pharmaceutical Sciences , 
2004 . 93 ( 1 ) : p . 124 - 131 . 
CITATIONS 17 . Verreck , G . , et al . , Characterization of solid dispersions 
of itraconazole and hydroxypropylmethylcellulose pre 
1 . Zhang , F . and J . W . McGinity , Properties of Sustained - pared by melt extrusion , part 1 . International Journal of 
Release Tablets Prepared by Hot - Melt Extrusion . Phar - 65 Pharmaceutics , 2003 . 251 ( 1 - 2 ) : p . 165 - 174 . 
maceutical Development and Technology , 1999 . 4 ( 2 ) : p . 18 . Brewster , M . , et al . , Solid dispersion comprising two 
241 - 250 . different polymer matrixes . 2004 : WO2004004683 . 
US 9 , 730 , 894 B2 
41 42 
19 . Baert , L . E . C . , G . Verreck , and D . Thone , Antifungal 35 . Evans , J . C . , et al . , Preparation of nanostructured 
compositions with improved bioavailability . 2003 : U . S . particles of poorly water soluble drugs via a novel 
Pat . No . 6 , 509 , 038 , W09744014 , U . S . Pat . No . 6 , 509 , 038 ultra - rapid freezing technology . Polymeric Materials Sci 
( B2 ) , US2001007678 ( A1 ) , EE9800304 ( A ) , ence and Engineering ( 2003 ) , 2003 . 89 : p . 742 . 
TR9801225T ( T2 ) , EE3902 ( B1 ) . 5 36 . Zimon , A . D . , Adhesion of Dust and Powder . 1982 , New 
20 . Rambali , B . , et al . , Itraconazole Formulation Studies of York : Consultants Bureau ( Plenum ) . pp 93 - 144 . 
the Melt - Extrusion Process with Mixture Design . Drug 37 . French , D . L . , D . A . Edwards , and R . W . Niven , The 
Development and Industrial Pharmacy , 2003 . 29 ( 6 ) : p . influence of formulation of emission , deaggregation and 
641 - 652 . deposition of dry powders for inhalation . Journal of 
21 . Verreck , G . , et al . , The Use of Three Different Solid 10 Aerosol Science , 1996 . 27 : p . 769 - 783 . 
Dispersion Formulations Melt Extrusion , Film - Coated 38 . Liu , J . and P . J . Stewart , Deaggregation during the 
Beads , and a Glass Thermoplastic System — To Improve Dissolution of Benzodiazepines in Interactive Mixtures . 
the Bioavailability of a Novel Microsomal Triglyceride Journal of Pharmaceutical Science , 1998 . 87 ( 12 ) : p . 1632 
Transfer Protein Inhibitor . Journal of Pharmaceutical 1638 . 
Sciences , 2004 . 93 ( 5 ) : p . 1217 - 1228 . 15 39 . Ticehurst , M . D . , et al . , Characterisation of the influence 
22 . Hulsmann , S . , et al . , Melt extrusion - an alternative of micronisation on the crystallinity and physical stability 
method for enhancing the dissolution rate of 17 ( beta ) . of revatropate hydrobromide . International Journal of 
estradiol hemihydrate . European Journal of Pharmaceu Pharmaceutics , 2000 . 193 : p . 247 - 259 . 
tics and Biopharmaceutics , 2000 . 49 ( 3 ) : p . 237 - 242 . 40 . Hu , J . , K . P . Johnston , and I . Williams , Robert O . , Rapid 
23 . Forster , A . , J . Hempenstall , and T . Rades , Characteriza - 20 release tablet formulation of micronized danazol powder 
tion of glass solutions of poorly water soluble drugs produced by spray - freezing into liquid ( SFL ) . Journal of 
produced by melt extrusion with hydrophilic amorphous Drug Delivery Science and Technology , 2004 . 14 ( 4 ) : p . 
polymers . Journal of Pharmacy and Pharmacology , 2001 . 305 - 311 . 
53 : p . 303 - 315 . 41 . Liversidge , G . G . and P . Conzentino , Drug particle size 
24 . Kearney , A . S . , et al . , Effect of polyvinylpyrrolidone on 25 reduction for decreasing gastric irritancy and enhancing 
the crystallinity and dissolution rate of solid dispersions absorption of naproxen in rats . International Journal of 
of the antiinflammatory C1 - 987 . International Journal of Pharmaceutics , 1995 . 125 ( 2 ) : p . 309 - 313 . 
Pharmaceutics , 1994 . 104 ( 2 ) : p . 169 - 174 . 42 . Liversidge , G . G . and K . C . Cundy , Particle size 
25 . Nykamp , G . , U . Carstensen , and B . W . Muller , Jet reduction for improvement of oral bioavailability of 
milling a new technique for microparticle preparation . 30 hydrophobic drugs . Part 1 : Absolute oral bioavailability 
International Journal of Pharmaceutics , 2002 . 242 ( 1 - 2 ) ; p . of nanocrystalline danazol in beagle dogs . International 
79 - 86 . Journal of Pharmaceutics , 1995 . 125 : p . 91 - 97 . 
26 . Carstensen , U . and B . W . Mueller , New process for the The above is a detailed description of particular embodi 
preparation of microparticles , useful e . g . for controlled ments of the invention . It will be appreciated that , although 
drug release , comprises encapsulating active agent in 35 specific embodiments of the invention have been described 
biodegradable polymer under heating , cooling and milling herein for purposes of illustration , various modifications 
in two stages to a fine powder . 2002 : DE10061932 . may be made without departing from the spirit and scope of 
27 . Reverchon , E . , Supercritical antisolvent precipitation of the invention . Accordingly , the invention is not limited 
micro - and nano - particles . Journal of Supercritical Fluids , except as by the appended claims . All of the embodiments 
The , 1999 . 15 ( 1 ) : p . 1 - 21 . 40 disclosed and claimed herein can be made and executed 
28 . Palakodaty , S . and P . York , Phase Behavioral Effects on without undue experimentation in light of the present dis 
Particle Formation Processes Using Supercritical Fluids . closure . 
Pharmaceutical Research , 1999 . 16 ( 7 ) : p . 976 - 985 . 
29 . Bleich , J . and B . W . Mueller , Production of drug loaded What is claimed is : 
microparticles by the use of supercritical gases with the 45 1 . A process for preparing a hot - melt extruded pharma 
Aerosol Solvent Extraction System ( ASES ) process . Jour ceutical composition comprising drug - containing particles 
nal of Microencapsulation , 1996 . 13 ( 2 ) : p . 131 - 139 . dispersed in a stabilizing and non - solubilizing carrier , the 
30 . Chen , X . , et al . , Preparation of cyclosporine A nano - process comprising : 
particles by evaporative precipitation into aqueous solu providing drug - containing particles of a therapeutic com 
tion . International Journal of Pharmaceutics , 2002 . 242 50 pound , wherein said particles have a mean particle 
( 1 - 2 ) : p . 3 - 14 . diameter of 100 microns or less and comprise one or 
31 . Chattopadhyay , P . and R . B . Gupta , Production of more amorphous or crystalline therapeutic compounds 
griseofulvin nanoparticles using supercritical CO2 anti dispersed in one or more adjunct stabilizers ; 
solvent with enhanced mass transfer . International Jour admixing said drug - containing particles with a stabilizing 
nal of Pharmaceutics , 2001 . 228 ( 1 - 2 ) : p . 19 - 31 . 55 and non - solubilizing hot - melt extrudable carrier that 
32 . Ghaderi , R . , P . Artursson , and J . Carlfors , Preparation of does not solubilize , or solubilizes 10 % drug weight or 
biodegradable microparticles using solution - enhanced less of , the drug containing particles to form a particle 
dispersion by supercritical fluids ( SEDS ) . Pharmaceutical carrier admixture ; and 
research , 1999 . 16 ( 6 ) : p . 676 - 681 . mixing and hot - melting extruding the charges particle 
33 . Phillips , E . M . and V . J . Stella , Rapid expansion from 60 carrier admixture to form the hot - melt extruded phar 
supercritical solutions : application to pharmaceutical maceutical composition ; wherein a substantial majority 
processes . International Journal of Pharmaceutics , 1993 . of the fine drug particles are not agglomerated or 
94 ( 1 - 3 ) : p . 1 - 10 . aggregated as a result of the step of hot - melt extruding . 
34 . Hu , J . , et al . , Improvement of Dissolution Rates of Poorly 2 . The process of claim 1 further comprising : preparing 
Water Soluble APIs Using Novel Spray Freezing into 65 the fine drug - containing particles by mechanical milling ; 
Liquid Technology . Pharmaceutical Research , 2002 . solution based phase separation technique ; freezing tech 
19 ( 9 ) : p . 1278 - 1284 . nique or a combination thereof . 
43 
25 microns . 
US 9 , 730 , 894 B2 
44 
3 . The process of claim 2 further comprising : preparing 12 . The process of claim 1 , wherein the stabilizing and 
the fine drug - containing particles by ball mill , jet mill , non - solubilizing carrier is selected from the group consisting 
grinding , mortar and pestle grinding , spray drying , com of a poloxamer , polyethylene oxide ; polypropylene oxide ; 
bined emulsification and evaporation , combined emulsifica polyvinylpyrrolidone ; polyvinylpyrrolidone - co - vinylac 
tion and solvent extraction , complex coacervation , gas anti - 5 etate ; acrylate and methacrylate copolymers ; polyethylene ; 
polycaprolactone ; polyethylene - co - polypropylene ; alkylcel solvent precipitation , precipitation with a compressed lulose ; hydroxyalkylcellulose ; hydroxyalkyl alkylcellulose ; antisolvent , aerosol solvent extraction system , evaporative starch ; pectin ; polysaccharide ; lipid ; wax ; mono , di , and tri 
precipitation into aqueous solution , supercritical antisolvent , glycerides ; cetyl alcohol ; steryl alcohol ; parafilm wax ; 
solution - enhanced dispersion by supercritical fluids , rapid hydrogenated vegetable and castor oil ; glycerol monoste 
expansion from supercritical to aqueous solutions , pressure arte ; polyolefin ; xylitol ; mannitol ; sorbitol ; alpha - hydroxyl 
induced phase separation , spray freezing into liquid , ultra acid ; enteric polymer ; and a combination thereof . 
rapid freezing , anti - solvent precipitation or a combination 13 . The process of claim 12 , wherein the stabilizing and 
thereof . non - solubilizing carrier is comprised of polyethylene oxide . 
4 . The process of claim 1 , the process further comprising : , 14 . The process of claim 1 , wherein the particles have a 
determining the temperature at which the therapeutic com 15 mean particle diameter of 50 microns or less . 
pound dissolves into the stabilizing and non - solubilizing 15 . The process of claim 14 , wherein the particles have a 
hot - melt extrudable carrier ; and / or determining the tempera mean particle diameter of 10 microns or less . 
ture at which amorphous drug in the fine drug - containing 16 . The process of claim 1 , wherein the particles have a 
particles begins to recrystallize . mean particle diameter of 1 micron or less 
5 . The process of claim 4 , wherein the therapeutic com 20 17 . The process of claim 1 , wherein greater than 75 % of 
pound is amorphous , and the step of hot - melt extruding is the particles have an average diameter of less than about 20 
conducted at a temperature that is at least 10° C . below the microns . 18 . The process of claim 17 , wherein greater than 75 % of temperature at which the therapeutic compound in the fine 
drug - containing particles begins to recrystallize . the particles have an average diameter of less than about 5 
6 . The process of claim 5 , wherein the step of hot - melt 
extruding is conducted at a temperature wherein the stabi 19 . The process of claim 18 , wherein greater than 75 % of 
lizing and non - solubilizing hot - melt extrudable carrier the particles have an average diameter of less than about 1 
melts . micron . 
7 . The process of claim 4 , wherein the therapeutic com - 30 20 . The process of claim 1 , wherein 5 % by number or less 
pound is crystalline , and the step of hot - melt extruding is 30 of the particles are present in the composition in agglomer 
conducted at a temperature that is at least 10° C . below the ated form . 
temperature at which the therapeutic compound dissolves 21 . The process of claim 1 , wherein the fine particles have 
into the stabilizing and non - solubilizing hot - melt extrudable been prepared by spray drying , mechanical milling , solution 
carrier . based phase separation technique , freezing technique , anti 
8 . The process of claim 7 , wherein the step of hot - melt 35 solvent precipitation , or a combination thereof . 
extruding is conducted at a temperature wherein the stabi 22 . The process of claim 21 , wherein the fine particles have been prepared by spray drying . lizing and non - solubilizing hot - melt extrudable carrier 
melts . 23 . The process of claim 1 , wherein the therapeutic 
9 . The process of claim 1 , wherein the drug - containing 40 compound is amorphous . 
particles comprise a therapeutic compound and one or more 24 . The process of claim 23 , which has been hot - melt 
adjunct stabilizers . extruded at a temperature that is at least 10° C . below the 
10 . The process of claim 9 , wherein the adjunct stabilizer temperature at which the therapeutic compound in the fine particles begins to recrystallize . is selected from the group consisting of sorbitan esters , 
polyoxyethylene sorbitan fatty acid esters , polyoxyethylene 45 25 . The process of claim 1 , wherein the therapeutic 
alkyl ethers , poloxamers ( polyethylene - polypropylene gly compound is crystalline . 
col block copolymers ) , sucrose esters , sodium lauryl sulfate , 26 . The process of claim 25 , which has been hot - melt 
oleic acid , lauric acid , vitamin E TPGS , polyoxyethylated extruded at a temperature that is at least 10° C . below the 
glycolysed glycerides , dipalmitoyl phosphadityl choline , temperature at which the therapeutic compound dissolves 
glycolic acid and salts , deoxycholic acid and salts , sodium 50 . into the stabilizing and non - solubilizing hot - melt extrudable 50 carrier . fusidate , cyclodextrins , polyethylene glycols , polyglyco 
lyzed glycerides , 27 . The process of claim 1 , wherein the composition has polyvinyl alcohols , polyacrylates , 
polymethacrylates , polyvinylpyrrolidones , phosphatidyl been hot - melt extruded at a temperature that is 100° C . or 
choline and derivatives , and cellulose derivatives and a less . 
combination thereof . 28 . The process of claim 1 , wherein the therapeutic 
11 . The process of claim 10 , wherein the adjunct stabilizer 55 compound is itraconazole . 
is comprised of a polyvinylpyrrolidone . * * * * * 
